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ABSTRACT 
 
Despite the effort of medicine, many potential drugs, during the development for clinical 
use, prove not to be able in achieving the central nervous system (CNS), due to the low 
permeability of the blood-brain barrier (BBB). In consequence, most CNS diseases are 
untreated. For that reason, there is an increasing interest towards nanotechnology applied to 
medicine in order to improve the treatments of brain diseases. An important field of 
nanotechnology applications to CNS is the development of nano-tools for drugs delivering, 
such as nanoparticles (NPs). In recent years, researchers have been working on several 
strategies to deliver drugs into the brain. They take advantage of the chance to modulate the 
chemical-physical surface properties of NPs, improving cell-NP interaction in order to 
adsorb, to carry compounds and to enhance drug delivery across the BBB. Nevertheless, 
current drug delivery systems are still associated with the low efficiency of targeting and 
crossing of the BBB. In this work, peptide functionalized NPs have been synthesized and 
characterized in order to target and cross the cerebral endothelium. The iron-mimicry 
moiety CRTIGPSVC (CRT) has been chosen as BBB targeting peptide, exploiting its 
ability to recognize the transferrin receptor overexpressed on the brain endothelium. 
Staquicini et al. reported the advanced specific transport ability of CRT through the BBB. 
Therefore in this work, biocompatible NPs made up of poly (D,L-lactic-co-glycolic acid) 
(PLGA)-block-polyethylene glycol (PEG) copolymer (namely PELGA) and functionalized 
with CRT has been synthesized and characterized. The behavior in targeting and transport 
ability of the NPs in mouse brain endothelial cells has been investigated, under flow 
conditions. In order to improve the translocation across the BBB, decreasing the lysosomal 
storage of CRT-NPs, gH625 peptide has been chosen as cell-penetrating peptide (CPP). 
gH625 is a membranotropic peptide, well known for its ability to penetrate cell membranes 
and transport a large variety of cargo molecules/materials inside the cells. We speculated 
that the conjugation of CRT and gH625 to nanoparticle, may improves its translocation 
efficiency across the BBB. To test this hypothesis, PELGA NPs functionalized with CRT 
targeting peptide and with the CPP gH625 has been designed. NP efficiency to target the 
BBB under static and flow conditions and to penetrate across the in vitro BBB has been 
evaluated. Results demonstrated the cooperative effect of NP functionalization with gH625 
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and CRT 1:2 in static and flow conditions with a relevant impact on NP transport across the 
cerebral endothelium.  
In order to investigate the effect of functionalized NP on transport across the cerebral 
endothelium, a flow-based in vitro BBB on chip has been engineered. The system more 
closely mimics in vivo environment and represents a valid BBB in vitro model since exerts 
the barrier function. Therefore, a study platform for drug delivery systems has been 
developed. The BBB model system is able to investigate the effects of dynamic conditions 
on specific targeting and transport across the brain endothelium of active molecules 
conjugated to nanocarriers. 
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1 CHAPTER 1 
1.1 INTRODUCTION 
1.1.1 Nanomedicine: the application of Nanotechnology to cross biological barriers 
 
Nanotechnology is the science which allows the study and possible applications of small 
materials from 1 to 100 nm. The basic concept is that materials behave in different and 
often useful ways at the nanoscale. Applications of these molecules are emerging in several 
scientific fields: chemistry, medicine, biology, physics, engineering 
1
. Some of them are: 
advanced drug delivery systems, medical diagnostic tools, such as "lab-on-a-chip", real 
time diagnostics for physicians, cooling chips or wafers to replace compressors in cars, 
refrigerators, air conditioners and multiple other devices, utilizing no chemicals or moving 
parts, sensors for airborne chemicals or other toxins, photovoltaics (solar cells), fuel cells 
and portable power to provide inexpensive, clean energy, new high-performance materials; 
and much more 
2
. Interest of most researchers is to exploit nanotechnology in the field of 
medicine, in particular diagnostic and therapeutic branches. Application of nanotechnology 
to medicine is also called ‘nanomedicine’ and appears to be a relatively recent trend. Basic 
nanotechnology approaches for medical application date back several decades 
3
. The main 
goal of nanomedicine is to improve the diagnosis and treatment of medical conditions 
including aging and ultimately for the improvement and extension of natural human 
biological structure and function. For this purpose, nanomedicine employs innovative ways 
to develop new approaches and therapies for treatment of diseases, including drug delivery 
4–8
. This approach consists in the administration of drugs associated with carriers. Drug is 
located in the cavity enclosed by the polymer membrane and is physically or uniformly 
dispersed in a polymer matrix capable to carry the drug in the target site and influence drug 
release by modulation of physical-chemical properties of the carriers. Other methods more 
innovative are based on nanoparticles (NPs), dendrimers, nanogel and nanoemulsions 
9,10
 
(Fig. 1). In general the use of a soluble macromolecular carrier for drug delivery allows to 
modify the pharmacokinetic properties (absorption-distribution-metabolism). The carrier 
used in drug delivery is generally a system having order of magnitude of micro and nano-
meter. The advantage of nanosystems, compared to microsystems, relies on the reduced 
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dimensions which allow the crossing of biological barriers, such as the blood-brain barrier 
(BBB). 
 
Wilson X. Mai  et al. Integr. Biol., 2013, 5, 19-28 The Royal Society of Chemistry 2013 
Figure 1. Nanocarriers for drug delivery across the BBB. 
 
1.1.2 Blood-Brain barrier 
 
In most cases endothelial cells in systemic vessels do not express continuous tight 
junctions. In fact, fenestrations are present between adjacent cells, so that molecules can 
pass through tissues. In the BBB only small (< 500 Da) or lipophilic molecules can cross 
the barrier. BBB separates the circulating blood side from the brain side. It is formed by 
cerebrovascular endothelial cells, surrounded by basal lamina and astrocytic perivascular 
end-feet linking to the neurons (Fig. 3). The main role of BBB is to preserve brain 
homeostasis and to prevent toxic substances from entering the brain. An important feature 
of this barrier is the low and selective permeability to molecules, which is due to its 
peculiar biological characteristics. These characteristics include:  the lack of fenestrations, 
low number of pinocytic vesicles, the presence of cell-cell junctions which are composed of 
smaller subunits, frequently biochemical dimers that are transmembrane proteins such as 
occludin, claudin, junctional adhesion molecule (JAM). Each of these transmembrane 
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proteins is anchored into the endothelial cells by another protein complex that includes ZO-
1 and associated proteins occluding junction between cells of vascular walls, the presence 
of an high number of tight junctions between adjacent endothelial cells, formed by an 
intricate complex of transmembrane proteins with cytoplasmic accessory proteins. The 
barrier properties of the BBB are determined also by specific transport mechanisms 
11
. 
Therefore, BBB structure reflects its function which severely regulates the transport of 
molecules to the brain. Nutrients exploit specialized transcellular mechanisms in order to 
enter into the CNS. Diffusion of substances into the brain can be divided into paracellular 
(between cells) and transcellular (across cells) diffusion, both of which are non-saturable 
and non-competitive. Paracellular diffusion does not occur to any great extent at the BBB, 
due to the tight junctions. In the case of transcellular diffusion, the higher is the 
lipophilicity of a substance the greater is the diffusion into the brain 
12
. They are crucial for 
the regulation of permeability. 
 
Figure 3: Schematic representation of the BBB. 
1.1.3 Transport mechanisms through the BBB 
 
The most simple way to cross the cell membrane is the passive diffusion. Non-polar solutes 
and lipid soluble, such as O2 and CO2, dissolve in the cell membrane and passively proceeds 
from high to low concentrations through the barrier, without any input of energy. This 
mechanism is called osmosis. Water-soluble substances such as penicillin are hampered in 
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getting through.  Specific transporters, carrier-mediated efflux, can transport essential polar 
molecules, such as amino acids, glucose and nucleosides into the brain. Active efflux 
carriers can intercept some of passively penetrating solutes (for example lipid soluble 
drugs) and pump them out of the endothelial cells via efflux transporters such as P-
glycoprotein. Carrier-mediated influx (passive or secondarily active) can transport essential 
polar molecules, such as amino acids, glucose, small peptides, into the CNS. Furthermore, 
TJ modulation may occur, which relaxes the junctions and entirely or partially opens the 
para-cellular aqueous diffusional pathway (polar solutes). Receptor-Mediated Transcytosis 
(RMT) can transport macromolecules: receptor on the apical plasma membrane recognizes 
and binds a RMT ligand (for example Insulin, Transferrin, Leptin, cytokines), peptide 
ligand mimetic or an anti-receptor antibody,  with subsequent transcytosis across the BBB. 
Adsorptive-Mediated Transcytosis (AMT) is induced by non-specifically negatively 
charged molecules such as avidin, cationised albumin and it is also transported across BBB. 
RMT and AMT are time- and concentration-dependent processes, which require energy. 
They are independent from their gradient concentration (Fig. 4). 
Transcytosis at the BBB starts with uptake either through clathrin-coated pits or caveolae, 
named endocytosis. These vesicles repel anionic molecules and require the interaction of a 
ligand with moieties expressed on the luminal side of endothelial cells. After interaction, 
endocytosis involves the invagination of the plasma membrane, in order to form vesicles 
able to transport molecules from outside to inside the cells. There are 2 kinds of cellular 
transcytosis: clathrin- and caveolin mediated. The first one allows the cells to introduce 
nutrients and regulatory molecules inside the cell. This mechanism requires a selective 
recognition of molecules from specific receptors which are express on the plasma 
membrane. This process is followed by the formation of the complex “Receptor-Ligand” in 
specific points of the membrane called clathrin-coated. Afterwards vesicles lose their 
clathrin coat and blend with an endosome.  Apical (or basolateral) endosome transfers 
material to recycling- basolateral (or apical) endosome. This vesicle is shuttled to the (brain 
side) plasma membrane and exocytosis occurs, releasing the vesicle’s content into the brain 
parenchyma. Alternatively, vesicle can also be sent to the lysosome for degradation of its 
content. Caveolae-coated vesicles, instead,  are involved in the internalization of ligand and 
messengers. It is coated by caveolin which links cholesterol on the plasma membrane, 
introducing itself inside the cell. After caveolae formation and its detachment from the 
plasma membrane as endocytic vesicles, caveolae is transported through the intracellular 
space and fuses with the basal endothelial surface, releasing its content into the interstitial 
space.  The new general strategies for delivering biologics into the brain employ the RMT 
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via. Such strategies involve the conjugation of a receptor-targeting moiety with the drug of 
interest. 
 
Nature Reviews Neuroscience © 2005 and Elsevier © 1996 
Figure 4. Potential routes for transport across the BBB. 
1.1.4 Strategies to overcome the BBB 
 
Conventional drug therapies for CNS related pathology, such as brain tumors, HIV 
encephalopathy, epilepsy, cerebrovascular diseases and neurodegenerative disorders, 
involve the use of strategies as the temporary and local breakage of the endothelium, 
intracerebral injections, to administer the active drug directly into the brain or introduction 
of a slow-release implant into the brain 
13
. Despite the efforts of medicine, the effectiveness 
of conventional drug treatments is limited. These treatments are often invasive, low 
effective for the patient and might cause several side effects: destroying the BBB 
temporarily leaves the brain vulnerable to infection and the insertion of solid implant can 
damage brain tissue. Therefore many potential drugs have failed and have been discarded 
during their development for clinical use due to the limitation in delivering them in 
sufficient quantity to the brain. Furthermore a lot of molecules which show promising 
therapeutic results in vitro, are larger than 500 Da and water soluble, so they are unable to 
enter brain tissue in significant amounts. Charged molecules and compounds that contain 
rotatable bonds have also a lower ability of penetration across the BBB 
14
. In addition, lipid 
solubility improves the crossing of BBB but reduces its solubility. To achieve efficient 
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treatments of the CNS, it is necessary to transport drug across the BBB 
15
. Nanomedicine 
applied to the treatment of the CNS diseases provides a valid alternative therapeutic 
approach to conventional  treatments. The challenge to win is achievement of CNS, 
reaching the threshold of a sufficient drug concentration, in order for it to be effective, 
avoiding side effects to healthy tissues (Fig. 5). 
 
Figure 5: Targeted therapy across the blood-brain barrier. 
1.1.5 Engineered-NPs for BBB crossing 
 
A promising strategy to control the delivery of drugs to their action site is represented by 
the use of nanocarriers, such as nanoparticles (NPs), dendrimers, nanogel and 
nanoemulsions. The surface functionalization of nanocarriers, by using chemical or 
biological moieties, offers the possibility to recognize and cross the endothelium through 
the binding of specific receptors and exploiting the mechanism of transcytosis 
16
.  Among 
the various methods used by researchers, RMT is considered the most common strategy for 
the active transport and has been widely exploited for brain targeting 
17,18
. The targeting 
moiety could be an endogenous RMT ligand, a peptide ligand mimetic, or an anti-receptor 
antibody. Upon intravenous administration, at least a portion of the RMT-targeted 
nanocarriers enters the brain by RMT. Many brain drug delivery strategies have focused on 
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RMT pathway for the delivery of many different biologics, following vesicular trafficking 
and avoiding endo-lysosomal storage.  Brain capillary endothelial cells overexpress 
different receptors such as transferrin (Tf), insulin and low-density lipoprotein 
19–26
. The 
transferrin receptor (TfR) was one of the first RMT systems studied for BBB drug delivery. 
In particular, TfR mediates iron delivery to the brain parenchyma via binding and 
intracellular trafficking of the iron-binding protein Tf 
27
. Internalization of the Tf-TfR 
complex leads to the endosomal compartments in which the acidification (pH < 5.5) allows 
the release of iron from the ligand. Iron is transported into the cytoplasm for utilization or 
storage, whereas the apo-transferrin (apo-Tf) remains tightly bound to its receptor until it 
reaches the plasma membrane. Here, the apo-Tf rapidly dissociates from the receptor at 
neutral pH 
28
. The free receptor, on the cell surface, is available for another cycle of RMT. 
The insulin receptor (IR) is responsible for the import of blood insulin into the brain via 
RMT. Use of insulin as an RMT-targeting vector has not been exploited, given both a short 
serum half-life of 10 min and the potential for exogenously administered insulin to cause 
hypoglycemia. The low density lipoprotein receptors, (LDLR) mediate the transport of 
lipoproteins and other ligands, such as ApoE, Apo B, Angiopep-2, across the BBB via 
RMT. Ligands, such as Tf, insulin and LDL, have high affinity for specific receptor but 
usually  are not efficient to enhance endocytosis of NP. In fact, to date, only a few studies 
have clearly demonstrated the therapeutic effect of targeted nanocarriers in the treatment of 
cerebral diseases 
29,30
. To further penetrate the brain endothelium, avoiding lysosomal 
accumulation of NPs, a possible strategy is the surface functionalization with bioactive 
peptides, such as cell penetrating peptides (CPPs). CPPs are short peptides of 5-40 amino-
acids with net positive charge, helical moment, amphipatic nature. CPPs enter cells 
presumably by means of their cationic groups initially interacting with negative charged 
residues of cell membrane. Several studies demonstrate the effectiveness of CPPs such as 
TAT, in promoting NP transport across the BBB 
31
. Great attention has been also directed 
towards CPP peptides, which take advantage of the non-toxic components of neurotoxins to 
overcome the BBB and reach the CNS. Neurotoxins as potential shuttles can be classified 
by origin: viral (for example Herpes simplex virus, Rabies virus), bacterial (Vibrio 
Cholerae, Clostridium botulinum) and animal (Bungarus candidus snake, Ophiophagus 
Hannah) 
32
. As reported, NPs functionalized with gH625, a viral fusion peptide derived 
from the glycoprotein gH of Herpes simplex type 1 facilitated the delivery of NPs across 
the BBB, leading to signiﬁcant higher cell uptake and crossing, bypassing the lysosomal 
entrapment 
33
. Despite the lack of site specificity, non-toxic moiety of neurotoxins could act 
on all cell membranes, leading to peripheral and unwanted side effects. Therefore, in order 
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to overcome the BBB, avoiding unwanted side effects to healthy tissues, it’s crucial to 
develop nanocarriers which are able to specific target and penetrate the BBB. 
1.1.6 Experimental models to study the BBB 
 
Understanding the BBB physiology is crucial to analyze its capabilities. Hereafter we 
describe the methods to investigate the effect of NP functionalization on the interaction 
with the BBB in order to improve therapeutic treatments to the CNS. Experimental systems 
available to study the BBB are: in vivo, ex vivo, in vitro, in silico.  
In vivo studies 
The most consolidated method to study transport across the BBB is to perform in vivo 
experiments because it allows to study whole brain microenvironment and biological 
processes in live animals and the results are clearly more reliable. In vivo studies might be 
carried out to assess brain transport, metabolism, and BBB disruption.  On the other hand 
main disadvantages are: ethical issues on the human brain, high costs and not allowing real-
time studies. Besides in vivo studies of the BBB are very difficult and only can be 
performed in animal experiments, such as in mice, and remains the need to translate the 
results in humans 
34
. 
Ex vivo studies 
Allowing experiment on living tissue in an artificial microenvironment outside the 
organism. The most used method for brain studies are slices. In slice, the cytoarchitecture 
of the tissue is maintained. Advantages of ex vivo studies are: controlled environment and 
provide the opportunity to study whole organs (impossible in living subjects). 
Disadvantages of this approach: post-mortem delay, allows short-term studies and the 
microenvironment is artificial 
35
. Main ex vivo studies on brain are: tight junctions, 
evaluation of brain capillary permeability.  
In silico studies 
In silico (computational) studies are performed by development of computational models 
using sophisticated algorithms. BBB In silico study tries to predict brain permeability to 
drugs and transporter properties. This approach is cheaper and is able to screen rapidly a 
large number of compounds and allows a reduction in the use of animals and reagents. 
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However, the major defect is that it does not consider other key factors such as the 
permeability, also appearing in the complex nature of BBB. Besides, conformation of 
molecules could provide false results 
36
. 
In vitro studies 
A valid alternative is provided by using in vitro models which offers the advantage of 
mimicking what happens at the biological level, ensuring the opportunity to have a highly 
controlled environment and to eliminate a large number of in vivo physiological variables in 
brain 
37
. They allow investigations that appear difficult to be performed in vivo, for example 
drug delivery to the CNS. In vitro model systems are able to reproduce the key 
physiological and biological characteristics of BBB in vivo archetype. To mimic such key 
characteristics, various systems have been developed to date 
38–43
. In particular, in vitro 
BBB models provide two compartments separated by the BBB, grown on a microporous 
membrane, which allows the exchange of molecules between the apical compartments and 
the basal compartments. Pore sizes of membranes available are: 0.4, 1, 3, 5, 8 µm, 
depending on the solute to be investigated. Research has been very much enhanced by the 
availability of Transwell, a commercial BBB in vitro system. Upper chamber of Transwell 
insert, generally functions as the vascular side while the bottom one acts as the 
parenchymal side. In vitro BBB systems include the use of endothelial monocultures of 
different origin: murine, rat, porcine, bovine, monkey, human cerebral endothelial cells. 
Cell lines or primary monocultures can be used. Cell lines are generated by 
immortalization, they reach the confluence in a few days, allowing an high number of 
experiments in a short time. Primary cell cultures are isolated from tissue explants and 
maintained in culture. They closely mimic the in vivo state but it’s difficult to remove 
surrounding cells from endothelial fraction 
44
. Besides, they lose their features in culture 
after few passages, going to senescence. Costs of monocolture model are moderate, but the 
major disadvantage of this model is the absence of stimulating factors of the neurovascular 
unit. In order to maintain brain endothelial phenotype and functionality, the presence of 
brain microenvironment is needed. In addition to brain endothelial layer, also astrocytes 
and pericytes can be co-cultured, improving barrier properties. In a double co-culture 
system, endothelial cells are cultured on an insert of the Transwell and astrocytes at the 
bottom site of the plate. In triple co-culture system endothelial cells and pericytes are 
cultured respectively on the top and bottom of the insert and astrocytes grow on the bottom 
of the plate 
39
. However, as reported in literature, the brain endothelial cells retain the 
microvascular barrier properties even without astrocytes and pericytes assistance 
45
. 
 
17 
 
1.1.7 Static versus dynamic in vitro BBB model 
 
Static in vitro systems, such as Transwell, still exclude the importance of in vivo 
physiological conditions, such as the shear stress exerted on the wall of the vessel, to which 
BBB endothelial cells are exposed (Fig.  6). Shear stress of blood flow may enhance the 
tightness of endothelial cells. Cells are stimulated, resulting a functional and phenotype 
alteration. Therefore, in recent years flow-based microfluidic in vitro BBB systems are 
developed in order to more closely mimic in vivo condition. Chip can be designed so that 
the channel dimension and the flow rate exerted on the cells, realistically simulate the 
physiological microenvironment 
46
. Besides, they also allow to carry out permeability 
studies in dynamic condition. To validate the BBB model, 3 methods can be employed: 
TEER measurement to evaluate the tightness of the layer, cell imaging and permeability 
assay to evaluate selectivity of the barrier to compounds 
47
. TEER is used to monitor cell 
growth and development of the tight junctions. To calculate TEER value in Ωcm2, 
resistance of the blank filter (Ri) is subtracted from cell layer resistance (Rf) at each time 
point and normalized for area (A).  
𝑻𝑬𝑬𝑹 =  (𝑹𝒇  −  𝑹𝒊) 𝑨 
However, the measured permeability could be wrongly estimated due to multiple layers 
grown on filter or due to holes and leakages. Others methods to validate the tightness is the 
evaluation of expression of tight junctions marker proteins by indirect immunofluorescence 
through confocal fluorescence analysis. In this case, barrier imperfections can be easily 
detected. Moreover, another approach to study the permeability is to quantify the crossing 
of detectable tracers. Permeability of the monolayer to compounds, for example Bovine 
serum albumin (BSA) or dextran at several molecular weights: 4-20-70 kDa, can be 
assessed by measuring the rate of diffusion across the membrane in flow condition from the 
donor chamber of the system to the acceptor chamber. The medium is collected at each 
scheduled time. Therefore the fluorescence is measured by fluorescence spectrophotometer 
and is converted to concentration. The solute permeability P of the monolayer is calculated 
according to the following equation.   
𝑷 =  (
∆𝑪𝑨
∆𝒕
) × 𝑽𝑨 (𝑪𝑫 × 𝑺)⁄  
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Where 
∆𝑪𝑨 
∆𝒕
 is the increase in fluorescence concentration in the acceptor chamber during the 
time interval ∆t, CD is fluorescence concentration in the donor chamber (assumed to be 
constant during the experiment), VA is the volume of the acceptor chamber, and S is the 
surface area of the filter 
34
.  
          A)                                                       B)   
Figure 6 . Static (A) and dynamic (B) in vitro models of the blood-brain barrier.  
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1.3 AIM OF THE THESIS 
 
Most conventional treatments are severely hindered from entering the brain parenchyma. 
Ability of nano-sized systems to specifically target and penetrate across the blood-brain 
barrier (BBB) can be exploited to an effective brain therapy. Physico-chemical properties of 
nanoparticles (NPs) such as, small size, possibility to being functionalized with ligands, 
ability to transport cargo and the potential capacity to access isolated parts of the body, 
including brain, create a lot of interest to develop NPs for the treatment of CNS diseases. In 
this contest the aim of this work is to design a new NP able to recognize and translocate 
across the cerebral endothelium and investigate the effects of physico-chemical parameters 
on targeting and crossing of the BBB, under dynamic conditions. It is widely reported that 
NPs enter the cells using a cell-mediated mechanism called endocytosis. After endocytosis, 
endosomes can fuse with lysosomes, determining the NP degradation or can transport their 
cargo by transcytosis process. Specific endogenous ligands, such as transferrin (Tf), insulin 
and low density lipoprotein are able to take advantage of the Receptor-Mediated-
Transcytosis (RMT) mechanism to cross the BBB. Surface functionalization of NPs with 
ligand-mimicking peptides allows to penetrate through the BBB and to achieve the CNS. 
Recent studies demonstrate in vitro and in vivo that CRTIGPSVC (CRT) peptide targets the 
complex Tf/TfR, improving the effectiveness in transporting cargo across the BBB, in a 
specific manner. CRT is an iron-mimicking peptide which can be exploited as RMT-
targeting ligand. The identification of overexpressed TfRs on the BBB is needful in order to 
target the cerebral endothelium exploiting RMT mechanism. To this aim for the first time a 
rapid, simple and quantitative methodology based on Isothermal Titration Calorimetry 
(ITC) coupled with bEnd.3 confluent cell layers cultured around biocompatible templating 
microparticles has been used in order to demonstrate the number of TfRs onto the cell 
membrane and study the energetics of their interaction with the transferrin. Data 
demonstrated that the value of TfRs/cell reveals a 100-fold increase in the number of TfRs 
per bEnd.3 cells compared to endothelial cells not of brain (HUVECs). 
In order to improve the NP transport across the cerebral endothelium, avoiding lysosomal 
entrapment, NP has been functionalized with CRT coupled with a cell-penetrating-peptide 
(CPP). It is reported that in vitro brain delivery of model NPs conjugated with the CPP 
gH625 (gH) is efﬁciently enhanced. gH is a membranotropic peptide, derived from Herpes 
simplex virus type 1. Nevertheless, because of their non-specific affinity to different cells, 
gH625-mediated brain delivery systems could show a non-specific distribution in the 
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human body, after systemic administration. Therefore, in this work, to overcome the CPP 
lack of specificity, we hypothesized that the synergic effect of CRT and gH conjugated to 
NPs should improve the targeting and crossing through the BBB. In order to demonstrate 
this hypothesis, in vitro biological characterization of dual-functionalized NPs has been 
performed. In the first step, sub-100 nm CRT-NPs, made up of a biodegradable poly (D,L-
lactic-co-glycolic acid) (PLGA)-block-polyethylene glycol (PEG) copolymer (namely 
PELGA), have been synthetized. Both PEG and PLGA meet FDA approval criteria for 
clinical use as drug adjuvants. Cellular uptake in static and flow conditions and ability of 
peptide to enhance NP crossing of a murine endothelial monolayer have been investigated. 
In the second step, we synthesized CRT and gH625 dual-functionalized PELGA NPs with 
three different ratios of peptides: gH/CRT: 33%-66% ; gH/CRT: 50%-50%; gH/CRT: 66%-
33%. Results of in vitro BBB crossing, in static condition, demonstrated that decoration 
with CRT peptide promotes NP overcoming of BBB. Moreover, NP transport of dual-
functionalized NPs is highest for gH/CRT_33/66. We also investigated how this NP 
functionalization can affects the targeting of NPs to BBB endothelium in a parallel plate 
flow chamber named Glycotech system. According to the NP crossing results, 
gH/CRT_33/66 NPs display the higher targeting ability. Because Transwell systems used 
for NP transport assays still exclude the importance of in vivo physiological conditions, 
flow-based microfluidic in vitro BBB system has been developed in order to more closely 
mimic in vivo environment. Firstly a new method to fabricate circular microchannels has 
been reported. The advantage of cell adhesion and growth in the circular shape compared to 
square microchannel has been also demonstrated. Cells are able to form an homogeneous 
monolayer that resembled the endothelial tissue of capillary. Hence, a new microfluidic in 
vitro BBB model system has been engineered. A protocol of cell seeding and culturing in 
the new microfluidic system has been developed. Data demonstrated the capability of the 
microfluidic device to allow the growth and the correct formation of the murine brain 
endothelial layer (bEnd.3) and to quantify the transport ability of functionalized NPs. 
These findings manifest a cooperative effect of gH and CRT peptides in enhancing 
transport across the BBB when exposed on NP in percentage 33%/66%, respectively. 
Therefore the novel NP could be regarded as a promising carrier to deliver drugs across the 
BBB for the treatment of brain diseases.  
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2 CHAPTER 2 
 
Active targeting and transport across the blood-brain barrier of CRTIGPSVC-
functionalized nanoparticles. 
 
2.1 ABSTRACT 
 
Brain drug delivery systems have been developed to bypass the blood-brain barrier (BBB) 
in order to therapeutically target central-nervous system (CNS) diseases. The most common 
strategy used from many nanocarriers to reach the brain is to exploit the BBB physiology. 
Both receptors and mimic-physiological ligands can be used to transport nanoparticles 
(NPs) into the CNS. Here, we present a new theranostic platform based on biodegradable 
nanoparticles functionalized with CRTIGPSVC (CRT) peptide, which functionally mimics 
the endogenous iron, recognizes selectively the brain endothelium and promotes the BBB 
crossing. In vitro experimental data indicate that NP functionalization with CRT peptide is 
a promising brain delivery system due to its high efficacy to translocate across the murine 
BBB, both in static and dynamic conditions. 
2.2 INTRODUCTION 
 
Drug transport to the brain for the treatment of CNS diseases is limited by the presence of 
the BBB. To overcome this barrier many delivery strategies have been attempted, such as 
local injection, induction of enhanced permeability 
1
. Among others, nanotechnologies play 
an important role in developing strategies for brain drug delivery. In the last decades, 
several methods have been designed to overcome or exploit the transport systems of the 
BBB. These strategies are based upon nanocarriers usage. The targeted delivery of 
nanocarriers represents the alternative strategy to conventional invasive and low effective  
brain treatments. A promising strategy to control the delivery of drugs in their action site is 
represented by the use of nanoparticles (NP). NPs are defined as particulate dispersions or 
solid particles with a size in the range of 1-100 nm. Depending on the method of 
preparation of NPs, it is possible to obtain "nanocapsules", where the drug is encapsulated 
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within a cavity formed by a single polymer membrane, or "nanospheres", where the drug is 
linked physically to the surface. By using of NPs, the drug can be transported to the place 
of action, encapsulating drug and enhances drug concentration in target tissues, in this way, 
lower doses of drug are required, minimizing undesirable side effects to healthy tissues. 
Some examples of NPs widely studied for drug delivery are liposomes, dendrimers and 
metal containing NP. Different types of NPs are getting closer to clinical use such as 
liposomes, solid lipid NPs, polymeric NPs, metal NPs, Quantum dots. An ideal NP should: 
1) recognize selectively the targeting tissue 2) promote brain drug delivery 3) have long 
circulation time 4) protect the cargo from enzymatic degradation 5) have low 
immunogenicity 6) have good biocompatibility 
3
. Usually, NPs enter the cell by endocytic 
pathway. After endocytosis, endosomes fuse with lysosomes, in which the acidification (pH 
< 5.5) allows the degradation of the content or can deliver the cargo across the BBB. In 
order to escape endo-lysosomal pathway and deliver the cargo across the BBB, the 
chemico-physical modulation of the NP surface plays major role in determining the fate of 
the particles. For example, when endogenous ligands bind to specific receptors, they are 
taken up into the brain endothelial cells by endocytosis. NPs functionalized with these 
ligands can be also taken up, enabling BBB-impermeable drugs to enter the BBB. 
Therefore, the surface functionalization of nanocarriers with specific ligands such as Tf, 
insulin and low density lipoprotein offers the possibility to recognize and cross the BBB 
endothelium via recognition of specific receptors, overexpressed by the cells, and through 
mechanism of transcytosis. Receptor-mediated transcytosis (RMT) is considered the most 
used strategy, among all the methods. The exploitation of RMT has already been proposed 
for the transport of biologics into the brain 
4–6
. Usually specific ligands only have high 
affinity for specific receptors, however often are inefficient to promote endocytosis 
7
. 
Therefore the main limitation of RMT is associated with the low efficiency of BBB 
crossing and the achievement into the CNS. One significant drawback of the RMT systems 
is their fairly ubiquitous expression, which leads to peripheral organ uptake. When this 
level of expression is combined with the fairly modest crossing capacity, relatively low 
levels of brain uptake result 
8
. Researchers have been focusing substantial effort on 
identifying new BBB RMT targets. Many of them were identified through the screening of 
combinatorial peptide libraries. Recently, Staquicini et al 
9
 have identified a new sequence 
CRTIGPSVC (CRT), able to recognize selectively brain endothelium and to enhance brain 
crossing of viral particles. TfR is highly expressed on immature erythroid cells, placental 
tissue, and rapidly dividing cells, both normal and malignant. Furthermore it is expressed 
on hepatocytes and endothelial cells of the BBB 
10
. TfR mediates iron delivery to the brain 
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parenchyma via binding and intracellular trafficking of the iron-binding protein Tf 
11
. 
Internalization of the Tf-TfR complex leads to the endosomal compartments in which the 
acidification allows the release of iron from the ligand. Iron is transported into the 
cytoplasm and is trancytosed, whereas the apo-transferrin (apo-Tf) remains tightly bound to 
its receptor until it reaches the plasma membrane. Here, the apo-Tf rapidly dissociates from 
the receptor at neutral pH 
12
. The free receptor, on the cell surface, is available for another 
cycle of RMT. Staquicini et al. demonstrated in vitro that the BBB targeting peptide CRT 
selectively interacts with apo-transferrin (apo-Tf) to induce allosteric conformational 
changes that functionally mimic iron through a non-canonical ligand-directed mechanism 
(Fig. 1) 
 
 
Figure 1: Transcytosis of the iron-mimicking CRT peptide. D. Nathanson and P. S. 
Mischel, “Charting the course across the blood-brain barrier,” J. Clin. Invest., vol. 121, 
no. 1, pp. 31–33, 2014. 
 
 Besides, in vivo it was demonstrated the internalization and transcytosis of targeted phage 
particles into the normal mouse brain. In order to develop a nanocarrier system able to 
target and cross the BBB, here we report the ability of CRT functionalized PLGA-PEG 
(PELGA) nanoparticles to target and cross the cerebral endothelium. PELGA NPs can 
provide better biocompatibility, higher reproducibility, higher pay-load properties, easiness 
in functionalization and excellent stability both in vitro and in vivo 
13
. In particular, it was 
recently reported on the versatility of PELGA nanoparticles as efficient drug delivery 
systems 
14–17
. In this work, we developed CRT-functionalized PELGA NPs by using the 
nanoprecipitation method, in order to evaluate the capability of this peptide to transport the 
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NP across the BBB. To address this issue, first, in vitro synthesis and characterization of 
peptide alone are performed. Second, CRT-NPs are validated in terms of cell type 
specificity, uptake and permeability to the BBB. Our results clearly demonstrate the ability 
of CRT peptide to target and cross the brain endothelium when conjugated to polymeric 
nanoparticles thus paving the way to the design of novel multifunctional nanocarriers for 
delivery of therapeutic agents to the central nervous systems (CNS).  
 
2.3 RESULTS AND DISCUSSION 
 
2.3.1 Expression analysis of Transferrin Receptor 
 
The delivery of iron into cells in general begins with diferric-Tf binding to the cell surface 
receptor 
18
. The TfR is an integral membrane glycoprotein consisting of two identical 
95.000-Da subunits linked by a disulfide bridge. Each subunit can bind one Tf molecule. 
TfR is a member of a class of cell surface receptors characterized by a rapid, constitutive 
internalization 
19
. In order to demonstrate that brain endothelium overexpresses the 
transferrin receptors, these ones were stained with TfR antibody in two different endothelial 
cell types: immortalized mouse brain endothelial cell line (bEnd.3) used as model of brain 
endothelium and primary human umbilical vein endothelial cells (HUVECs) used as model 
of endothelium not of brain. Confocal images for each cell type were acquired and the 
fluorescence intensity of TfR was analyzed by imageJ software. Results in Fig. 2A show 
that in BBB endothelium TfR signal is higher than endothelium not of brain (HUVECs). In 
particular the fluorescence intensity is about 3-fold higher for bEnd.3 compared to the 
control, demonstrating that bEnd.3 overexpress TfR. Data were confirmed by confocal 
images of TfR immunostaining in bEnd.3 (Fig. 2B) and in HUVECs (Fig. 2C).  
We also investigated the Tf binding to its receptors in near-physiological conditions when 
cells were grown on dextran microbeads ranging from 67 to 80 µm named Cytodex 
20
. We 
obtained the energetics of ligand/receptor interactions and simultaneously the number of 
receptors on the cells by using Isothermal Titration Calorimetry (ITC). ITC is an important 
methodology to determine the ligand specificity to its receptor and is able to distinguish 
between specific and nonspecific interactions. The binding curve shown in Fig.1 provided 
the complete thermodynamic profile (i.e., binding constant (Kb), enthalpy change (∆H°), 
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entropy change ( ∆S°), Gibbs energy change (∆G°) of the interaction between Tf/TfR. The 
revealed affinity between transferrin (Tf) and transferrin receptors (TfRs) in both systems is 
very high, Kd values are in the order of nM. The value of TfRs/cell reveals a 100-fold 
increase in the number of TfRs per bEnd.3 (Fig. 2D) compared to endothelial cells not of 
brain (HUVECs) (Fig. 2E).  
 
 
Figure 2: (A) Expression analysis of TfR in bEnd.3 and HUVEC cells. Data are presented 
as the mean ± SD (n = 30), (*) P < 0.001. Confocal images of Transferrin receptor 
expression in bEnd.3 (B) and HUVECs (C). Green: Transferrin receptor; blue: nuclei. Bar 
50 µm. (D) ITC raw data for titration of Tf solution (1µM) into the solution of bEnd.3 cells 
(1800000 cells/mL) cultured on Cytodex microbeads (A) The solid circles are the 
experimental data obtained by integrating the raw data and subtracting the heat of Tf 
dilution into the buffer. The solid line represents the best fit obtained with the independent-
binding site model (B). (E) ITC raw data for titration of Tf solution (0.1µM) into the 
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solution of HUVEC cells (5600000 cells/mL) cultured on Cytodex microbeads (A). The 
solid circles are the experimental data obtained by integrating the raw data and subtracting 
the heat of Tf dilution into the buffer. The solid line represents the best fit obtained with the 
independent binding site model (B). 
After cell seeding, the surface of Cytodex beads appears rough compared to original beads 
indicating the presence of the cells on it. Moreover, confocal microscopy images further 
confirm the presence of a confluent layer of cells on the Cytodex surface (Figs. 3 A, B). In 
particular, phalloidin staining of the actin cytoskeleton demonstrates the correct spreading 
of the cells (Fig. 3 C). 
 
Figure 3: Phase contrast microscopy micrographs of Cytodex microsphere suspension 
before (A) and after (B) cell seeding. Maximum projection of z-sectioning images obtained 
by confocal microscopy with 10 × objective of a Cytodex microsphere after bEnd3 cell 
seeding (C-F). Actin microfilaments are stained in red by Phalloidin-TRITC (C), cell nuclei 
are represented in blue by DAPI (D) and the Cytodex is acquired in transmitted light (E). 
Merge of the three channels is reported in F. 
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2.3.2 Peptide synthesis and characterization 
 
The CRT peptide (seq. CRTIGPSVC) was synthesized using the standard solid-phase-
method (SSPM).  Fig. 3 shows the structure (A) and mass spectrum (B) of peptide. In order 
to investigate the intracellular distribution, CRT peptide was conjugated with the 
Rhodamine B dye. The rhodaminated peptide was obtained with good yields (30–40%) 
after RP-HPLC purification. In Fig. 4 the structure (C) and mass (D) spectrum of 
rhodaminated-peptide are reported.  
 
 
Figure 4. A, C structures and  B, D mass spectra of CRT and rhodaminated-CRT, 
respectively.  
 
2.3.3 Peptide cytotoxicity and uptake. 
 
In order to choose the optimal peptide concentration for cellular uptake assays, we tested 
the effect of peptide on cytotoxicity. Results (Fig. 5 a) show that for bEnd.3 cells, after 1 
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and 4 hours of incubation for each concentration of peptide (1-5-10-20 µM), viability is 
almost 100%. HUVECs viability, decrease below 80%, for 20 uM of peptide after 4 hours 
of exposure. Thus, 10 uM CRT-Rhod was chosen as the optimal concentration for peptide 
uptake. To verify the cellular uptake of peptide, bEnd.3 and HUVECs were observed by 
confocal microscope after 1h and 4h of incubation with CRT-Rhod, at 37°C. As shown in 
Fig. 5 b) an higher spotted fluorescence was noticed within the cytoplasm of bEnd.3 at 4h 
than 1h of incubation. A slight fluorescence signal was observed in HUVECs cells only 
after 4h of exposure. No significant fluorescence signal was observed within the cytoplasm 
of HUVECs cells after 1h of incubation with peptide. Thus, CRT-Rhod peptide showed a 
significantly higher binding to brain endothelial cells compared to endothelial cells not of 
brain, according with cellular TfR expression. 
 
Figure 5: a) Alamar blue assay of CRT peptide in HUVECs and bEnd.3 after 1 and 4 h of 
incubation. Cell viability was expressed as percentage respect to the non-treated control 
cells and b) confocal images of untreated (A) or pretreated bEnd.3 with CRT peptide 10 
µM for 1h (B) and 4h (C). Untreated HUVECs (D) and uptake after 1h (E) and 4h (F) of 
incubation with CRT peptide. Red: CRT peptide; blue: nuclei. Bar 50 µm. 
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2.3.4 NP synthesis and characterization 
 
Blank and CRT functionalized NPs were synthesized by nanoprecipitation method. To  
investigate the effect of the peptide functionalization on the size of nanoparticles, we 
performed dynamic light scattering (DLS) measurements. After functionalization, the 
hydrodynamic size of nanoparticles with CRT in aqueous medium at pH 7 was found to be 
respectively 92.06 ± 1.53 nm, with polydispersity of 0.15 and size of blank nanoparticles 
was 88.24 ± 1.62 nm, with polydispersity values of  0.15 (Table 1).  
To elucidate the colloidal stability of functionalized nanoparticles, which is a crucial 
parameter correlated to their functionalization, measurements of the zeta potential were 
carried out. For NPs alone z potential was  -27.40 ± 0.66 mV and for peptide functionalized 
NP was -26.10 ± 1.17 mV. The size difference and the more positive charge of CRT-NP 
compared to blank NPs are probably due to the peptide exposure on NP surface. It is widely 
accepted that at high values of z-potential (over 30 mV, positive or negative) the 
electrostatic interactions between particles are strong enough for electrostatic stability, 
while at intermediate values of z-potential, near their isoelectric point, particles can 
flocculate. 
NP 
Size [nm]
a)
 
± SD 
PDI 
ʐ Potential a) 
[mV] ± SD 
Blank 88.24 ± 1.62 0.15 -27.40 ± 0.66 
CRT 92.06 ± 1.53 0.15 -26.10 ± 1.17 
 
Table 1: Size measurements and z potential of blank and CRT-NPs. 
a)
 Mean value ± SD, 
n=3. 
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2.3.5 NP cytotoxicity and uptake 
 
The cytotoxic effect of blank and CRT-NPs was evaluated by Alamar Blue Assay on 
bEnd.3 cells. Results in Fig. 6  do not indicate a reduction of viability of cells treated for 
24h with both blank (A) and functionalized NPs (B) at several NP concentrations in 
bEnd.3. In order to investigate the cell specificity of CRT-NPs, bEnd.3 and HUVECs were 
incubated for 24h at 37°C with blank and CRT NPs [0.05 mg/mL]. After incubation, to 
verify cellular uptake of NPs, cells were fixed and stained with DAPI. Samples were 
observed by confocal microscope. As shown in Figs. 6 (B-G) both blank (Fig. 6C) and 
CRT-NPs (Fig. 6D) are internalized by bEnd.3 cells. NPs are distributed as spots, mainly 
localized in the perinuclear region of the cell. An higher spotted fluorescence was detected 
within bEnd.3 incubated with CRT-NPs compared with blank NPs. No significant  
fluorescent signal was noticed for blank NPs (Fig. 6 F) and for CRT-NPs (Fig. 6 G) 
internalized by HUVECs. A perinuclear distribution of both blank and CRT-NPs  was 
observed within bEnd.3.  
 
 
Figure 6: Cytotoxicity assay of blank and CRT-NPs in bEnd.3 after 1 day of incubation 
(A). Cell viability was expressed as percentage compared to the non-treated control cells. 
Confocal images of untreated bEnd.3 (B) or pre-treated with blank NPs (C) or CRT-NPs 
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(D) after 24h. Untreated HUVECs (E) and uptake of blank (F) and CRT-NPs (G) after 24 h. 
Red: CRT peptide; blue: nuclei. Bar 50 µm.   
NP adhesion assay under flow condition by using Glycotech system. 
Therefore we investigated how the surface functionalization could affects the targeting of 
NPs to the cerebral endothelium in a parallel plate flow chamber Glycotech system, a 
commercial device mimicking hydrodynamic conditions in the microcirculation. The 
volumetric flow rate Q (10 µl/min) was fixed to be equal for all the experiments. Based on 
these data, the mean velocity 𝑈 =
𝑄
𝑤ℎ
 within the chamber was of about 0.066 mm/sec the 
shear rate 𝑆 =
6𝑄
ℎ2𝑤
  was 1.55 𝑠𝑒𝑐−1 and the shear stress at the wall 𝜏𝑤 = µ 𝑆 was 1.86 × 
10
-3
 Pa. The mean velocity used for the experiments is comparable with the blood velocity 
in the human capillary vessel that was calculated between 0.01 and 0.1 mm/sec (Ganong et 
al 2003) and the shear rate and the shear stress at the wall were sufficiently small to allow 
adhesion of nanoparticles to endothelial cells 
21
. Fluorescent images analysis demonstrated 
that CRT NPs have the higher adhesion ability to bEnd.3 monolayer compared to blank 
NPs (Fig. 7). Data are reported as the percentage of mean gray value normalized for the 100 
% of NP fluorescence intensity. As shown, the mean gray value percentage of CRT-NPs 
was found 0.79 % against blank NPs 0.44 %.  
 
Figure 7: Adhesion assay of blank and CRT NPs to bEnd.3 monolayer under flow rate 10 
µl/min by using Glycotech system. (*) P < 0.005. 
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2.3.6 NP transport across the BBB  
 
bEnd.3 cells are able to form a confluent cell layer. The monolayer mimics permeability 
properties of the BBB 
22
. The ability of CRT-NP to promote NP crossing of the bEnd.3 
confluent monolayer was investigated in Transwell system (Corning). Data reported in Fig. 
8 show that CRT-NPs cross more efficiently the endothelial layer than blank NPs. More 
precisely the permeability values of the BBB to functionalized NPs was 4.64 × 10
-6 
cm/sec 
and for blank NPs was 3.16 × 10
-6
 cm/sec. 
 
 
 
 
Figure 8: Effect of peptide functionalization in NP crossing of a confluent bEnd.3 cell 
monolayer. (*) P < 0.005. 
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2.4 MATERIALS AND METHODS 
  
2.4.1 Cell culture 
 
Immortalized mouse cerebral endothelial cells, (bEnd.3; American Type Culture 
Collection, Manassas, VA) were grown at 37°C and 5% CO2  in DMEM with 4.5 g/L w/o 
phenol red (Gibco), supplemented with 10% FBS, 3.7 g/L sodium bicarbonate and 4 mM 
glutamine, 100U/mL penicillin and 0.1 mg/mL streptomycin, 1% non essential aminoacids. 
bEnd.3 used in all experiments were at passage 21-30. 
Primary human umbilical vein endothelial cells (HUVECs; Lonza), used from passage 3 to 
8, were cultured in Medium-200 (Cascade Biologics) supplemented with LSGS kit (Life 
Technologies). 
2.4.2 Cell staining 
 
The expression of TfR in bEnd.3 and HUVECs cells was investigated by immune-staining 
with anti-Transferrin Receptor antibody (Abcam). 1 × 10
4 
bEnd.3 and HUVECs cells were 
seeded on round glass coverslips placed in 24 well plates. 24h after seeding, cells were 
fixed with 4% paraformaldehyde for 10 min. Tf receptors were localized by incubating 
samples first with the blocking buffer (BB) (0.5% BSA in PBS) and after with the anti-
Transferrin polyclonal primary receptor (1 µg/mL) overnight at 4°C. Then, the Alexa-488 
anti-Rabbit secondary antibody (Invitrogen) diluted in BB was incubated 1 h at room 
temperature (RT). To detect actin filaments, FITC-Phalloidin (Invitrogen) was used. After 
fixation and permeabilization, bEnd.3 cells were incubated for 30 minutes at RT. For nuclei 
staining DAPI (Sigma) was used.  
 
2.4.3 Expression analysis of Transferrin Receptor  
 
After cell staining for TfR and DAPI, in order to verify the expression of Transferrin 
Receptor, bEnd.3 and HUVECs were observed by confocal microscope (MP Leica TCS 
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SP5). 30 images of cells by type were acquired and analyzed. Transferrin expression 
analysis was performed by using imageJ software 1.44p, calculating the mean gray value of 
TfR signal. Mean gray value is the sum of the gray values of all the pixels in the selection 
divided by the number of pixels. To evaluate the area of each cell, the ROI manager tool 
allowed to pick out the shape cell region. Hence the mean gray value was calculated for 
each cell area. 
2.4.4 Cell seeding on Cytodex 
 
Pyrex glass vial was coated with Sigmacote (Sigma) for 5 min before use to prevent cell 
adhesion on the walls. Dextran microcarrier beads (Cytodex® 3 purchased from Sigma) 
were weighed in the vial and swelled with PBS for 3 h, at RT under gentle stirring. 
Afterwards the vial was autoclaved to prevent contamination. After sterilization, Cytodex 
suspension was decanted and PBS was removed to resuspend the beads at a concentration 
of 5 mg/ml in cell culture medium. 2 ml of Cytodex suspension were transferred into each 
well of a low attachment 6-well plate (Corning). 8 × 10
5 
cells in 100 µl of cell culture 
medium were added to the Cytodex in the well. In order to allow cell adhesion to the 
surface of the microspheres, the 6-well plate was kept under stirring at 80 rpm overnight in 
incubator at 37 °C and 5 % CO2. Stirring was stopped for 1 min every 15 min for the first 3 
h from the seeding. After overnight incubation, 7 ml of Cytodex with adhered cells were 
collected and cells were fixed with 4 % paraformaldehyde for 10 min before ITC analysis. 
Cell adhesion on Cytodex was monitored by phase contrast microscopy.  We assume that 
all the cells seeded were attached on the microbeads.  
 
2.4.5 ITC experiments 
 
 Isothermal titration calorimetry (ITC) ITC experiments were performed using a Nano ITC 
Low Volume from TA Instruments (Lindon, UT, USA) with a cell volume of 170 μL. All 
solutions were accurately degassed before the ITC experiments to avoid the formation of air 
bubbles in the calorimeter cell. The sample cell was loaded with bEnd.3 or HUVEC cells 
cultured on Cytodex microbeads in PBS buffer solution, Tf instead was loaded into the 
computer-controlled microsyringe in the same buffer conditions. Injections were started 
after baseline stability had been achieved. Titration experiments were carried out at 298 K, 
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10 injections of 5 μL of Tf 1- 0.1 µM were added to the bEnd.3 or HUVEC cells cultured 
on Cytodex microbeads (1800000 - 5600000 cells/mL) every 250 seconds. Control 
experiments were carried out to calculate the heat of dilution for Tf in PBS solution. All the 
measurements were conducted at a continuous stirring rate of 250 rpm.  Raw data were 
obtained as a plot of heat released against time and featured as a series of peaks for each 
injection. The calorimetric enthalpy for each injection was calculated after correction for 
the heat of Tf dilution, the area under raw data peaks was integrated  by the analysis  
software  of the instrument (NanoAnalyze software, version 2.4.1 (TA Instruments)) to 
obtain a plot of enthalpy change per mole of injectant (Tf) against the number of TfRs per 
cell.  From the number of cells/mL was calculated the number of cells for each experiment. 
The number of TfRs was calculated taking into account the moles of added Tf, until the 
saturation occurs, this value correspond to half of the TfRs present in the sample cell. Holo 
-transferrin was previously shown to bind to the receptor with a stoichiometry of one Tf 
molecule per TfR monomer (stoichiometry Tf-TfR 2:1) . Each experiment was repeated up 
to three-five times in order to ensure reproducibility. Integrated heat data obtained for the 
titrations were ﬁtted using a nonlinear least-squares minimization algorithm to a theoretical 
titration curve, using NanoAnalyze software, version 2.4.1 (TA Instruments). (reaction 
enthalpy change in kJ mol-1), (binding constant in M-1), and n (number of binding sites) 
were the ﬁtting parameters obtained by the equivalent and independent binding sites model 
(Supporting Information, Equations S1-S13).  The remaining thermodynamic parameters of 
the interaction were calculated using the Eq. 1 
 ΔbG
° =  −RT ln Kb (R =  8.314 J mol
−1 K−1, T = 298 K)                                      (1)                   
 
and Eq. 2:   
       T ∆bS
° =  ∆bH
° − ΔbG
°                                                                                       (2)                       
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2.4.6 Peptide synthesis and characterization 
 
 CRT peptide was synthesized using standard solid-phase-9-fluorenyl methoxy carbonyl 
(Fmoc) method, by means of an automatic peptide synthesizer. Peptide was cleaved from 
the resin by means of standard TFA/TIS/Water (95/2.5/2.5) solution and then precipitated 
in cold ethyl ether. Purified CRT and was obtain by RP-HPLC starting from 5/95 (v/v) 
acetonitrile (ACN)/water solution containing 0.1% v/v TFA. 
2.4.7 Rhodamine coupling procedure  
 
Rhodamine-peptide conjugation was performed on solid-phase by a standard coupling 
procedure: peptides (1 eq), HBTU (5 eq), DIPEA (10 eq), and Rhodamine-B (5 eq) in 
anhydrous DMF. The reacting mixture was continuously stirred for 30 minutes at room 
temperature. After a second coupling procedure, Rhod-peptide was cleaved from resin and 
precipitated in cold ethyl ether. The reaction products were verified by analytical LC-MS 
and then purified by RP-HPLC using a 20/80 (v/v) acetonitrile (ACN)/water solution 
containing 0.1% v/v TFA.  
2.4.8 Peptide cyclization 
 
Purified CRT peptide was cyclized by air-oxidation method to allow the formation of the 
intra-chain disulfide bond between the two cysteine residues. Briefly, cysteinyl peptides 
(0.1 mg/mL) were dissolved in 0.1 M sodium carbonate (pH 8) and left to stand open to 
atmosphere under vigorous magnetic stirring until the reaction is complete (48 h). The 
products were monitored by LC-MS analysis. Cyclic peptide was lyophilized and purified 
as described above. 
2.4.9 PLGA-CRT conjugate  
 
The PLGA-Peptide conjugates were synthesized by a standard HBTU coupling procedure. 
Briefly, for CRT and Ctrl peptides, PLGA (1 eq), HBTU (5 eq), OximaPure
®
 (5 eq), 
DIPEA (10 eq), and Peptide (1.5 eq) were dissolved in anhydrous DMSO for 48h at room 
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temperature. For gH625 peptide PLGA-NH2 (1 eq), HBTU (10 eq), OximaPure
®
 (10 eq), 
DIPEA (20 eq), and Peptide (2 eq) were used. The adducts were purified from unreacted 
reagents using dialysis bags (MWCO 6-8 kDa) against pure water and lyophilized. The 
reaction products were verified by 
1
H-NMR spectroscopy. 
2.4.10 PELGA 
 
 PLGA-PEG copolymer (namely PELGA) was synthesized via a coupling reaction between 
PLGA and PEG. Briefly, the carboxyl group of PLGA has been reacted with the terminal 
hydroxyl group of PEG: 1 eq of PLGA, 4 eq of PEG, 0.4 eq DMAP and 2 eq of DCC were 
dissolved in 10 mL of anhydrous DCM. After the reaction (2 days, RT, inert atmosphere), 
bidistilled water. Then DCM was evaporated and the mixture was dissolved in 10 mL of 
DMSO, filtrated and dialyzed (MWCO 6-8 kDa) for 1 day against ACN and for 2 days 
against water. Pure product was recovered after lyophilization and checked by 1H-NMR 
spectroscopy. 
 
2.4.11 Amino-PLGA 
 
 PLGA was functionalized with ethylenediamine which act as a bridge between PLGA and 
Rhodamine (or peptide C-terminus) carboxylic groups. Briefly, 30 mg of  PLGA 502h, 10.3 
mg of DCC, 8.7 µl of DIPEA , 10.0 µl of ethylenediamine were dissolved in 2.5 mL of 
anhydrous DCM. After the reaction (1 day, RT, inert atmosphere), the residual DCC was 
changed into dicyclohexylcarbodiurea (DCU) by adding 10 µL of bidistilled water. Then 
the solution was filtered and precipitated dropwise into cold methanol, centrifuged and then 
placed under vacuum overnight. Pure product was checked by 1H-NMR spectroscopy. 
2.4.12 Rhodamine-PLGA 
 
 PLGA-Rhodamine conjugation were performed by a standard coupling procedure: PLGA-
NH2 (1 eq), HBTU (5 eq), DIEA (10 eq), and Rhodamine-B (5 eq) in anhydrous DMSO for 
24 h at RT and then purified by dialysis bags (MWCO 6-8 kDa) against water for 3 days. 
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2.4.13 NP preparation  
Rhodaminated PELGA-Peptide nanoparticles were prepared by nanoprecipitation method. 
Briefly, the proper amounts of copolymers and conjugates (Table 2) were dissolved in 
acetone and the obtained solutions mixed; final volume was adjusted to 1.3 mL. 
Afterwards, the solution was added dropwise (6 mL/h) with a syringe pump into 12.5 mL 
of distilled water under magnetic stirring (400 rpm). The solution was kept under magnetic 
stirring until all the organic solvent was evaporated (3-5 h) and the obtained NP suspension 
was sterilized with 0.22 µm membrane filter. Finally, the volume of the solution was 
reduced to 1 mL using Amicon
®
 Ultra-4 centrifugal filter. 
The final NP concentration (mg/mL of polymeric species) was estimated by fluorescence 
intensity measurements of Rhodamine-PLGA using a spectrofluorometer (Perkin Elmer) 
compared to fluorescence intensity of the initial NP concentration before filtration. 
       Pelga (mg) Plga-Rho (mg) Plga-CRT (mg) Plga (mg) mg tot 
Blank NP 1 0.4 - 0.8 2.2 
CRT NP 1 0.4 0.4 0.4 2.2 
 
Table 2: Amount of copolymers used for blank and CRT-NPs preparation. 
2.4.14 NP characterization 
Measurements of size and ζ-potential of NPs after filtration were made with a Zetasizer 
Nano-ZS (Malvern Instruments, Worcestershire, UK).  
2.4.15 Cytotoxicity assay 
Cell viability was quantified by the Alamar Blue Assay (Invitrogen) and compared to non-
treated cells, which were used as a control. Briefly, 1 × 10
4
 bEnd.3 and HUVECs cells were 
seeded in a 96-well and incubated for 1 and 4 h with Rhod-CRT at different concentration 
1-5-10-20 µM. Cytotoxicity of the negative control peptide was also investigated. For NP 
cytotoxicity assay, bEnd.3 cells were incubated for 24h with blank NPs and CRT-NPs at 
several concentrations: 0.050, 0.025, 0.012, 0.006, 0.003 mg/mL. Alamar Blue Assay was 
performed according to the manufacturer’s procedure. Absorbance of Alamar Blue reagent 
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solution was read at 570 nm and 600 nm by using a spectrofluorometer (Wallac 1420 
Victor2, Perkin–Elmer, USA). All experiment were performed in triplicate.  
2.4.16 Cellular uptake experiments  
To perform peptide and NP uptake experiments about 5 x 10
4 
bEnd.3 and HUVECs cells 
were seeded on round glass coverslips placed in 24 well plates. Cells were incubated for 1 
and 4 h with CRT-Rhod 10 µM and for 24 h with NPs at 37°C and 5% CO2. After 
incubation, samples were washed two times with PBS to remove non internalized peptide 
or NPs and fixed with 4% paraformaldehyde for 20 min. Finally, cell nuclei were stained 
with DAPI. Samples were observed by confocal MP microscope. 
2.4.17 Glycotech assay 
To perform NP adhesion assays, 4 × 10
5
 bEnd.3 were seeded on round glasses (dia 60 mm) 
placed in Petri dishes (100 mm dia). The experiments were performed after 3 days from the 
seeding. Adhesion assay to an in vitro model of BBB grown on the glass coverslip were 
performed by using Glycotech system. The system consists of a PMMA flow deck with 
inlet and outlet bores, a silicon gasket and a glass coverslip (Fig. 8). The silicon gasket 
separates the acrylic flow deck and the glass and defines the flow area. The gasket used in 
the present experiments had a thickness h of 0.01 in and a width w of 1 cm. The inlet bore 
is connected to a syringe-pump through a silastic tube and the outlet bore to a reservoir. 
The volumetric flow rate Q (10 µl/min) was fixed to be equal for all the experiments. Based 
on these data, the mean velocity has been calculated with the following equation 𝑈 =
𝑄
𝑤ℎ
 
within the chamber and the shear rate 𝑆 =
6𝑄
ℎ2𝑤
 and the shear stress at the wall 𝜏𝑤 = µ 𝑆 
being 1.2 × 10
-2
 dyn s/cm
2  
the viscosity of the medium. NP solutions at the final 
concentration of 0.2 mg/mL in cell culture medium supplemented with 40 mM HEPES 
buffer were flushed by using a 5 mL syringe allocated on a syringe pump. Flow is driven 
through the parallel plate flow chamber for 1h at 37°C in a plexiglass incubator. At the end 
of the experiment, cells were fixed after  2 washes with PBS to remove non adherent NPs. 
The percentage of mean gray value was analyzed by using imageJ software 1.44p.  
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A     B   
Figure 8: A) Schematic of the Glycotech flow chamber for studying cellular interaction. B) 
Picture of Glycotech system. 
2.4.18 Permeability assay by Transwell system  
bEnd.3 were seeded at a density of 3 × 10
4
 cells/cm
2 
on Transwell permeable inserts 
(6.5mm diameter, 3 µm pores size; Corning Incorporated, Corning, NY). Permeability 
experiments were performed on the monolayer 7 days after cell seeding, allowing sufficient 
time for the cells to develop the junctions between cells. On the day of experiment, 
Transwell insert filter was washed with PBS, and then the media of the donor chamber was 
filled with 150 µL cell culture medium w/o phenol red containing 0.1 mg/mL of blank NPs 
or CRT-NPs while the acceptor chamber was filled with 400 µL cell culture medium 
without phenol red. The samples of 400 µL were drawn every 30 min for 2h from the 
acceptor chamber and were then replaced with the same amount of fresh medium. The 
fluorescence tracer concentration in the samples was determined by a spectrofluorometer 
(Victor, Wallac, PerkinElmer) and the excitation and emission wavelengths were set to 557 
and 578 nm, respectively, for NPs. The permeability to NPs of the bEnd.3 monolayer was 
calculated according to the following equation, 
                                                 
SC
V
t
C
P
D
A
A





 
Where is the increase in fluorescence concentration in the acceptor chamber during the time 
interval, is fluorescence concentration in the donor chamber (assumed to be constant during 
the experiment), is the volume of the acceptor chamber, and S is the surface area of the 
filter. The experiments were performed in triplicate.  
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2.4.19  Statistical analysis 
Results were expressed as mean ± standard deviation (SD). Statistical analyses were 
performed using a one-way analysis of variance (ANOVA). Results repeats were compared 
by analysis of variance (ANOVA), and a p value < 0.05 were considered statistically 
significant. 
2.5 CONCLUSIONS  
The nanoparticle ability to recognize the brain endothelium is an important requisite for 
successful brain therapy. The design of targeted delivery carriers has garnered significant 
attention in recent years because of the potential to achieve highly localized delivery to 
brain endothelium 
5,8,23
. In order for a targeted delivery system to be effective, the 
functionalization with ligands which are able to bind specifically receptors overexpressed 
on the BBB is important in determining the drug delivery. In light of the wide variety of 
ligands proposed, in this work, CRT peptide has been chosen to selectively target the brain 
endothelium. Staquicini et al. previously demonstrated that phage clones displaying the iron 
mimicking CRT peptide, were able to target the complex Tf/TfR mediating the transport of 
the corresponding viral particles into the normal mouse brain. In this work, firstly, the 
overexpression of Tf receptor in brain endothelium has been demonstrated. After 
rhodaminated-peptide synthesis and characterization, viability of cells incubated with the 
CRT-Rhod at several concentration has been evaluated until 4h. Therefore, 10 µM of 
peptide has been chosen for bEnd.3 and HUVECs uptake assay. As demonstrated by 
confocal images, the uptake of CRT peptide in bEnd.3 is higher than HUVEC cells, 
according to the expression of cell Tf receptors. In order to investigate the ability of CRT to 
target  nanoparticle to the cerebral endothelium selectively, NPs exposing CRT peptide 
have been synthesized and characterized. Confocal images show that bEnd.3 uptake of 
CRT-NP is higher than blank NP, on the contrary, no significant NP uptake was noticed in 
HUVECs both for blank and CRT-NPs. Therefore the ability of CRT peptide to carry the 
NP to the brain endothelium, selectively was also demonstrated in vitro. To verify the CRT-
NP adhesion ability to murine cerebral endothelium under dynamic condition, Glycotech 
assay was also performed. In order to mimic physiological  blood microcirculation velocity, 
10 µl/min was setted as flow rate. For peptide functionalized NPs the percentage of mean 
gray value was found 1.8 times higher than blank NPs, thus CRT peptide is able to target 
the BBB also under flow condition. Afterwards the ability of CRT-NP to cross the cerebral 
endothelium, was also demonstrated. The rate of CRT-NP transported across the BBB is 
1.5-fold higher than blank NPs.  
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Taken all together, our results are promising in the light of improving the BBB targeting of 
potential therapeutic nanosystems, holding advantageous alternative for the treatment of 
CNS diseases. 
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3 CHAPTER 3 
 
Synergic effect of double functionalization with peptides in promoting NP transport 
across the cerebral endothelium. 
 
3.1 ABSTRACT 
The main obstacle in the treatment of Central-Nervous-System (CNS) diseases is the blood-
brain barrier (BBB). In order to overcome this barrier, a new potential brain delivery 
system has been developed for specific targeting and transport through the BBB, based on 
dual-functionalized polymeric nanoparticle (NP). The ability of nanoparticle functionalized 
with CRTIGPSVC (CRT) peptide able to promote the specific transport across the BBB has 
been demonstrated in the previous chapter. In this work, in order to avoid nanoparticle 
accumulation inside lysosomal compartments, enhancing efficiency in crossing the BBB, 
the nanoparticle functionalization with CRT was coupled with the cell-penetrating Peptide 
(CPP) gH625 (gH). The aim is to investigate the efficacy of NP functionalized with CRT 
peptide and gH625 in promoting the translocation across the cerebral endothelium. Co-
localization studies, adhesion and permeation assays across in vitro brain endothelial 
model, under dynamic conditions have been investigated. Results establish that the 
cooperative effect of CRT and gH on NPs may change the distribution of NP in the cell and 
strengthen the BBB crossing of NPs 
1
. 
3.2 INTRODUCTION 
In order to overcome the BBB, reaching the Central-Nervous-System (CNS), the 
modulation of physic-chemical properties of NPs such as surface charge, size and 
functionalization, play an important role in mediating their interactions with cell membrane 
and their intra-cellular fate. Several strategies have been developed to deliver drugs across 
BBB and increase the survival rate of patients in the CNS treatments. To combine targeting 
and crossing strategies, some researchers developed dual-functionalized carrier systems for 
targeted drug delivery across the BBB. For example functionalization with Transferrin (Tf) 
which is able to target selectively the BBB and reach the brain by Receptor-mediated-
transcytosis (RMT) and with a cell penetrating peptide (CPP) due to translocate across the 
BBB 
2,3
. However, the main limitation of RMT is associated with the low efficiency of 
BBB crossing and the achievement into the CNS. The aim of this work is to develop a new 
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nanoparticle able to enhance the crossing efficiency through a double peptide 
functionalization with gH625 (gH) and CRT peptides and to characterize the NP by using 
an in vitro BBB. In a previous work, it has been demonstrated that gH625-functionalized 
polystyrene NPs facilitate the delivery of nanoparticles across the murine BBB, leading to 
significant higher cell uptake and crossing 
4,5
. gH625 is a membranotropic peptide, derived 
from the glycoprotein H (gH) of the Herpes simplex virus type 1. gH625 interacts with 
model membranes, merging with them and is able to traverse the membrane bilayer and to 
transport a cargo, like quantum dots, liposomes, NPs, and dendrimers into the cytosol and 
across the BBB 
6,7
. Surface modification of NPs with gH625 may change the classical 
intracellular fate of endocytic pathway, mediating the lysosomal escaping of NPs and 
enhancing the translocation across the BBB. In this work, we synthesized gH625-
functionalized PLGA-PEG-NPs (PELGA-NPs), never reported before in a BBB in vitro 
analysis. Because of their non-specific affinity to different cells, gH625-mediated brain 
delivery systems could show a non-specific distribution in the human body, after systemic 
administration. Receptor mediated transcytosis (RMT) is the most common strategies used 
by researchers to target the cerebral endothelium, since brain endothelial cells express 
different receptors. In the previous chapter, the ability of CRT peptide to specifically 
transport PELGA NPs across the in vitro BBB was demonstrated. CRT is a cyclic iron-
mimicking peptide which may be used as the Receptor Mediated Transport (RMT)-
targeting ligand 
8
. Receptor transport caveolae-mediated pathway allows the specific 
transport of NPs to the CNS 
9
. CRT binds to apo-Tf, causing it to adopt its iron-bound holo-
Tf conformation, which recognizes TfR and gain access to the brain side. Therefore, in this 
work, to overcome the CPP lack of targeting specificity, we hypothesized that the coupling 
of gH625 to CRT on the surface of NPs may enhance NP transport across the murine 
cerebral endothelium (Fig. 1).  
 
Figure 1: Schematic synthesis of dual-functionalized NPs with CRT and gH625 peptides 
for the active targeting and crossing of the cerebral endothelium. 
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Dual-functionalized NPs, with 3 different ratios of peptides gH/CRT: (i) 50% - 50% (i) 
33% - 66% (iii) 66% - 33% have been synthesized and the effects of the functionalization 
on the penetration of PELGA NP through an in vitro BBB model based on bEnd.3, have 
been investigated. In order to study the contribution of both CRT and gH peptides in the 
trans-endothelial ability to cross the in vitro BBB, dual-functionalized NP formulations 
were compared to blank and mono-functionalized nanoparticles: CRT-NPs and gH-NPs. 
Reported here is that gH/CRT_33/66 NP promotes the targeting and crossing through an in 
vitro BBB under dynamic condition. 
 
3.3 RESULTS AND DISCUSSION 
 
3.3.1 NP characterization 
To investigate the size and z-potential of NPs, dynamic light scattering (DLS) 
measurements, in aqueous medium were performed. The hydrodynamic size of NPs, after 
filtration, was found to be 88.24 ± 1.62 nm, 92.06 ± 1.53 nm, 84.53 ± 0.60 nm for blank, 
CRT-NP and gH-NP and 80 ± 1 nm, 78 ± 2 nm, 76 ± 1nm for gH/CRT_66/33, 
gH/CRT_50/50, gH/CRT_33/66 respectively, with polydispersity values of ca. 0.15, 
indicating a narrow distribution of the particle size used for all the experiments. Z-potential 
of 3 types NPs were almost the same: -27.40 ± 0.66 mV for blank NPs, -26.10 ± 1.17 mV 
for CRT-NPs, -13.83 ± 0.11 mV gH-NPs, -22.4 ± 0.5 mV for gH/CRT_66/33 , -23.8 ± 0.9 
mV for gH/CRT_50/50 , -20.0 ± 0.5 mV for gH/CRT_33/66 (Table 1). A more positive 
charge was shown for gH-NPs and this is probably due to the positive charge of the amino-
acid chain. 
 
Table 1: Size and Zeta potential measurements of blank NPs and different NP 
functionalizations. 
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3.3.2 Co-localization studies 
To further investigate the fate of NPs, the intracellular distribution of them by co-
localization experiments within endocytic compartments, namely lysosomes, was followed. 
After 24h of incubation, samples were fixed with PF 4% for 10 min and observed by 
confocal microscope after lysosomes staining with LAMP-2. As shown, Fig. 2 blank, CRT-
NPs, gH-NPs, gH/CRT_66/33, gH/CRT_50/50 and gH/CRT_33/66 NPs are internalized by 
the cells and they have different intracellular localizations.  Blank NPs and CRT-NPs are 
distributed as spots mainly localized in the perinuclear region of the cell. Both blank and 
CRT-NPs partially co-localize with LAMP-2. Conversely, gH-NPs have a cytoplasmic 
distribution. No significant co-localization with lysosomes has been noticed for gH-NPs. 
On the other hand, localization of dual-functionalized NPs changes as a function of the 
formulation. Lysosomal distribution is linearly increasing with the CRT amount in the 
formulation, likewise, cytoplasmic distribution is linearly increasing with the gH amount, 
according with NP distribution of CRT and gH-NPs. 
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Figure 2: Colocalization of blank NPs (A,D); CRT-NPs (B,E); gH-NPs (C,F); 
gH/CRT_33/66 NPs (G,J); gH/CRT_50/50 NPs; (H,K); gH/CRT_66/33 NPs (I,L) with 
lysosomes after 24h incubation in bEnd.3 cells. Red: NPs; green: LAMP-2. Bar 50 µm. 
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3.3.3 NP transport across the BBB in static system 
In order to study the contribution of both CRT and gH peptides in the trans-endothelial 
ability to cross the BBB, dual-functionalized NP formulations were compared to mono-
functionalized NPs: CRT-NPs and gH-NPs. After 7 days of culture bEnd.3 cells were able 
to form a confluent cell layer, as described previously. Data reported in Fig. 3 show that 
CRT-NPs and gH/CRT_33/66 NPs cross more efficiently the endothelial layer compared to 
blank NP. In particular, among mono-functionalized NPs, CRT have the highest ability in 
NP transport across the in vitro BBB with a permeability of 4.64 × 10
-6
cm/s. 
 
No significant 
permeability of NP was found for gH functionalization (3.60 × 10
-6
 cm/s) compared to 
blank NPs (3.17 × 10
-6
 cm/s); among bi-functionalized NPs gH/CRT_33/66 permeability 
was 7.48 × 10
-6
 cm/s; gH/CRT_50/50 NPs was 4.50 × 10
-6
 cm/s and for gH/CRT_66/33 
was 3.50 × 10
-6  
cm/s. Data demonstrated that the increasing of CRT amount in dual 
functionalized NP formulation increases NP transport. Thus, gH/CRT_33/66 NPs have the 
highest of trans-endothelial crossing ability. 
 
Figure 3: Permeability of bEnd.3 cell monolayer to blank, CRT, gH, gH/CRT_33/66, 
gH/CRT_50/50, gH/CRT_66/33 functionalized NPs.  
3.3.4 Adhesion assay by using Glycotech system 
In order to predict the in vitro targeting ability of the NPs to a cerebral endothelium under 
flow conditions, parallel plate flow chamber Glycotech assays were performed, as 
 
55 
 
described in the previous chapter. Among dual functionalized NP formulations, 
gH/CRT_33/66 NPs have the highest of trans-endothelial crossing ability and was chosen 
to assess whether these NPs could adhere to the BBB also under dynamic conditions. 
Confocal images for each NP type were acquired and analyzed by imageJ software. Fig. 4 
compares the adhesion ability (Fig. 4A) and localization (Fig. 4 B) of blank NPs, CRT-NPs, 
gH-NPs and gH/CRT_33/66. Data are reported as the percentage of mean gray value. As 
shown, CRT-NPs and gH/CRT_33/66 NPs display the higher targeting ability at 10 µl/min 
flow rate (0.79 and 0.97 %, respectively) compared to blank NPs (0.44%). Percentage of 
mean gray value for gH-NP was found equal to 0.60%.  
 
 
Figure 4: (A) NP adhesion ability to bEnd.3 under flow condition 10 ul/min. P *= <0.05; P 
**= <0.0005. (B-I) confocal images of NPs in bEnd.3 after the experiments. B,F blank 
NPs; C,G gH-NPs; D,H CRT-NPS; E,I gH/CRT_33/66. Red: NPs; blue: nuclei. Bar 50 µm. 
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3.4 MATERIALS AND METHODS 
3.4.1 Synthesis of peptides 
All the peptides were synthesized using standard solid-phase-9-fluorenyl methoxy carbonyl 
(Fmoc) method. The sequences are shown in Table X. gH 625 and CRT peptides were 
cleaved from resin by means of standard TFA/TIS/Water (95/2.5/2.5) solution and then 
precipitated in cold ethyl ether. Purified CRT and Ctrl peptides were obtain by RP-HPLC 
starting from 5/95 (v/v) acetonitrile (ACN)/water solution containing 0.1% v/v TFA. For 
gH625 peptide purification a 20/80 ACN/water solution 0.1% v/v TFA was used. 
3.4.2 Synthesis of co-polymers 
PLGA-peptides conjugate: The PLGA-Peptide conjugates were synthesized by a standard 
HBTU coupling procedure. Briefly, for CRT, PLGA (1 eq), HBTU (5 eq), OximaPure® (5 
eq), DIPEA (10 eq) and Peptide (1.5 eq) were dissolved in anhydrous DMSO for 48h at 
room temperature. For gH625 peptide PLGA-NH2 (1 eq), HBTU (10 eq), OximaPure® (10 
eq), DIPEA (20 eq), and Peptide (2 eq) were used. The adducts were purified from 
unreacted reagents using dialysis bags (MWCO 6-8 kDa) against pure water and 
lyophilized. The reaction products were verified by 1H-NMR spectroscopy. 
Amino-PLGA, PELGA and Rhodamine-PLGA synthesis were described in the previous 
chapter. 
 
3.4.3 NP synthesis and characterization 
Functionalized-NPs were synthesized by nanoprecipitation method, according with the 
manufacturer’s procedure described in the previous chapter. All copolymers of each type of 
NP were dissolved in 1.2 mL of acetone (Table 2) 
10
. 
 
Table 2: Mass of copolymers of blank NP, gH-NP, CRT-NP, gH/CRT_66/33 NP, 
gH/CRT_50/50 NP, gH/CRT_33/66 NP 
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Mean size, size distribution and ʐ-potential of NPs were determined by laser light scattering 
measurements (Zetasizer Nano ZS, Malvern Instruments, UK) on a 0.1 mg/mL suspension 
of NPs in water (Table 2). 
3.4.4 Cell culture 
Mouse cerebral endothelial cells, bEnd.3 cells (American Type Culture Collection, 
Manassas, VA) were grown in DMEM with 4.5 g/L glucose, 10%  Foetal Bovine Serum 
(FBS), 3.7 g/L sodium bicarbonate, and 4 mM glutamine, 1% non-essential amminoacids, 
100 U/mL penicillin and 0.1 mg/mL streptomycin in 100 mm diameter cell culture dish, in 
a humidified atmosphere at 37 °C and 5% CO2. Cells used in all experiments were at 
passage 22–30. 
3.4.5 Co-localization studies 
Indirect immunofluorescence against endocytic markers may give information about the 
endocytic mechanisms underlying nanoparticle cellular uptake. The co-localization 
experiments are carried out on 70% confluent cells seeded on glass coverslips. All the 
reagents and solutions are prepared as described following. For co-localization 
experiments, with lysosomes, about 1 × 10
4  
bEnd.3 were seeded on the round 12 mm-
diameter glass coverslips placed in 24 well plates. Cells were incubated for 24 h with 
gH/CRT_33/66 NPs,  gH/CRT_50/50 NPs; gH/CRT_66/33 NPs, bEnd.3 were firstly rinsed 
twice with PBS to remove non-internalized NPs and fixed with 400 µl of 4% 
paraformaldehyde at room for 10 min. For lysosomes staining, cells fixed were 
permeabilized with 0.05% saponin-PBS for 10 min and incubated with FBS-PBS 10% for 
20 min at room temperature to block unspecific sites. Lysosomes were localized with rabbit 
1:150 anti-LAMP-2 polyclonal (Abcam, 1mg/mL) primary antibody for 1 hour at room 
temperature in a humidified chamber and with  1:200 AlexaFluor 488 anti-rabbit secondary 
(1 µg/mL) antibody for 30 min. After mounted the coverslips on glass slides with 
PBS/glycerol (1:1) solution, immunofluorescence analyses were performed by means of 
confocal laser scanning microscope 
3.4.6 Permeability assay to NPs in Transwell system  
bEnd.3 were seeded at a density of 3 × 10
4
 cells/cm
2 
on Transwell permeable inserts 
(6.5mm diameter, 3 µm pores size; Corning Incorporated, Corning, NY). Permeability 
experiments were performed 7 days from the seeding, allowing sufficient time for the cells 
to develop the junctions between cells. On the day of experiment, Transwell insert filter 
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was washed with PBS, and then the media of the donor chamber was filled with 150 µL cell 
culture medium w/o phenol red containing 0.1 mg/mL of gH/CRT_33/66 NPs, 
gH/CRT_50/50 NPs; gH/CRT_66/33 NPs while the acceptor chamber was filled with 400 
µL cell culture medium without phenol red. The samples of 400 µL were drawn every 30 
min for 2 h from the acceptor chamber and were then replaced with the same amount of 
fresh medium. The fluorescence tracer concentration in the samples was determined by a 
spectrofluorometer (Victor, Wallac, PerkinElmer). 
3.4.7 NP adhesion assay to BBB by using Glycotech system. 
Glycotech assay was performed according to the manufacturer’s procedure described in the 
previous chapter. The volumetric flow rate Q (10 µl/min) was fixed to be equal for all the 
experiments.  
3.5 CONCLUSIONS 
The aim of this work was to characterize the effect of functionalization of biodegradable 
nanoparticles with 2 synthetic peptides in enhancing targeting and transport across the 
cerebral endothelium. Sub-100nm PELGA NPs were successfully synthesized with 3 
different ratios of CRT and gH peptides by using nanoprecipitation method. Results clearly 
indicate that NPs are internalized by the cells. NPs show different intracellular localization. 
Blank and CRT NPs have a lysosomal localization on the other hand, gH-NPs have a 
mainly cytoplasmic distribution. For bi-functionalized NPs, increasing the amount of gH in 
NP formulations decreases the lysosomal distribution, on the contrary, increasing the 
amount of CRT decreases the cytoplasmic signal.  NP transport results demonstrated that 
CRT-NPs and gH/CRT_33/66 NPs have the higher transport ability compared to blank 
NPs. In particular, the permeability of the cerebral endothelium to gH/CRT_33/66 and 
CRT-NPs is about 2.5 and 1.5 times higher than blank NPs, respectively. Burdo et al. 
11
 
demonstrated that iron is transported across endothelial cells both bound to Tf (holo-
transferrin) and not bound to Tf (apo-transferrin). Several works reported that after 
endocytosis in brain endothelium, the complex Tf-TfR-iron is transported in coated vesicles 
to lysosomes, in which the presence of the iron chelating component desferrioxamine 
removes the iron from the complex. Then, the iron is transported across the membrane of 
the vesicle into the cytoplasm and is transcytosed, by still unclear mechanism. Fisher et al. 
[7] identified iron transport proteins such as ferritin for iron transcytosis, Mc Carthy et al. 
identified ferroportin [8]. On the other hand, apoTf-receptor complex is sorted into 
recycling endosomes to the blood on the luminal membrane 
14,15
. Then, co-localization 
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studies according with NP transport results, suggest that after the internalization, the 
complex CRT iron mimicking peptide-Tf-TfR is transported to lysosomes at pH 5-5.5 and 
CRT-NP from Tf/TfR is removed. Then, CRT-NP is transported into the basal 
compartment separately. On the contrary, the cytoplasmic distribution of gH-NPs is 
probably due to the working mechanism of gH peptide that promotes lipid membrane-
reorganizing processes, through fusion involving temporary destabilization and subsequent 
reorganization of the membrane 
6
. However, no significant crossing ability was observed 
when gH625 is exposed on PELGA NP. Probably when gH-NPs are synthesized, peptide 
does not assume the correct conformation, then gH625 is able to recognize lipid membrane 
of cells but does not exert its activity. To further investigate the NP targeting ability under 
flow condition, Glycotech system assays were performed. In order to obtain a mean 
velocity comparable with the blood velocity in human capillaries, the experiments were 
carried out using a flow rate of 10 µl/min. Data reported as the percentage of mean gray 
value indicates that gH/CRT_33/66 formulation has the highest targeting ability to the BBB 
under flow conditions. More precisely the percentage of gH/CRT_33/66 and CRT-NPs  is 
about 2.2 and 1.8 times higher than blank NPs, respectively, according to previous results 
of NP transport. No significant adhesion ability was found for gH-NPs and this can be 
ascribed to the lacks of specificity to the BBB of gH.  
Taken all together these findings indicates that for dual functionalized NPs, a cooperative 
effect of gH and CRT peptides when exposed on NP in percentage 33%/66%, respectively 
was demonstrated. Probably peptides in gH/CRT_33/66 NP formulation are able to assume 
the correct conformation and to exert their activity, promoting NP transport across the BBB 
in a synergic manner. The new nanocarrier, made up of FDA-approved materials, could be 
regarded as a promising strategy for administration of therapeutical compounds to the 
brain. 
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4 CHAPTER 5 
 
Microchannel mimicking microvascular capillary: a low cost platform for endothelial 
cell culture. 
 
4.1 ABSTRACT  
 
In order to mimic closely in vivo microvasculature we developed circular microchannels for 
endothelial cell growth. However, nowadays, a simple, low cost, and versatile method to 
fabricate circular microchannels is still missing. Here, we report on a fast, inexpensive, 
flexible and reproducible method to fabricate circular microchannels by coupling spin 
coating with micromilled square microchannels. The proposed method is based on the 
balance between the displacement of liquid PDMS induced by centrifugal forces and the 
surface tension that tends to keep the liquid accumulated especially in the corners, which 
become therefore rounded. To show the versatility of the described experimental study we 
prepared a variety of rounded microchannels, including branched and PMMA-PDMS 
hybrid configuration microchannels. Finally, an endothelial cell layer was formed by 
culturing brain endothelial bEnd.3 cells inside the proposed circular microchannels. Results 
demonstrated a more successful adhesion, growth, and homogeneous distribution of the 
cells along the circular microchannel than those observed in the square microchannel used 
as a control (Vecchione et al., 2016).  
4.2 INTRODUCTION 
 
Microfluidics is a micro-technological field that deals with the handling of fluids and 
dispersions of nano and micro-objects (Andersson and van den Berg, 2003; Valencia et al., 
2012; Whitesides, 2006). Interestingly, microfluidics provides important advantages over 
classical systems for cell and tissue cultures by displaying microchannels and structures 
that can mimic the physiological parameters of in vivo models (Haeberle and Zengerle, 
2007; Ziolkowska et al., 2011). Many researchers use circular microchannels with 
endothelial cells to replicate cardiovascular flow conditions in in vitro models (Borenstein 
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et al., 2010; Choi et al., 2013; Hochmuth, 2000; Lee, 2000). The advantage of circular 
microchannels over square microchannels in mimicking blood vessels for endothelial cell 
culture has also been recently demonstrated by an MIT research group that developed a 
rapid casting of patterned vascular networks for perfusable engineered three-dimensional 
tissues (Miller et al., 2012). The use of circular microchannels reduces the flow stagnation 
phenomenon present at the edges of square microchannels due to the symmetrical duct 
velocity profiles (Huang et al., 2012). Conversely, endothelial cells grown on the bottom of 
a square microchannel are subjected to a varying shear stress that influences their 
elongation, differentiation, and growth. (Seo et al., 2004). Together with the strong use in 
microvascular capillary field, the use of circular microchannels is convenient in the 
preparation of cylindrical or round microparticles, as well as circular fibers and cell-laden 
hydrogels (Chung et al., 2012; Dendukuri et al., 2007; Dendukuri et al., 2006) and to 
control microparticle migration (D'Avino et al., 2012; Romeo et al., 2013). Recently, open 
microchannels have also been used for cell growth or to flux fluids by capillary effect 
without using pump systems (Faid et al., 2005; Sia and Whitesides, 2003). Both 
applications may benefit from a circular microchannel shape as in the case of closed 
microchannels. 
Various methods to fabricate polymeric microchannels have been reported depending on 
the end goal of industrial mass production or rapid prototyping at the research laboratory 
level, including photolithography coupled with wet etching, reactive ion etching, stamp 
based techniques, such as soft lithography, hot embossing and injection molding, as well as 
ablating technologies like conventional machining, laser ablation and finally direct 3D 
printing (Fiorini and Chiu, 2005; Kim et al., 2008; Whitesides et al., 2001; Wu and Gu, 
2011; Zhao et al., 1997). Direct 3D printing can easily produce rounded microchannels, but 
with some limitations in the resolution, while more complex techniques -such as wet 
etching or reactive ion etching- can be tuned to produce rounded and smaller microchannels 
(Camp et al., 2008). During the last decade several research groups have developed new 
techniques for the fabrication of circular microchannels. For example, recently Abdelgawad 
et al. presented an innovative approach to fabricate circular microchannels from square 
geometry using a pressurized air stream inside PDMS-filled microchannels. This technique 
lacks the ability to create branches, while curved structures and long circular channels may 
be not uniform (Abdelgawad et al., 2011). Alternatively, mechanical micromachining 
techniques, such as micromilling, proved to be an effective approach to fabricate complex 
3D micro-scale features on metals and polymers (Chen et al., 2014; Dornfeld et al., 2006). 
However, microchannels obtained by micromilling technology exhibit a high roughness 
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profile (Ogilvie et al., 2010), while in many applications a very smooth surface is required 
(Hetsroni et al., 2005; Zhang et al., 2013).  Recently, by exploiting the surface tension 
phenomenon, it has been demonstrated that microlenses can be obtained by spinning liquid 
PDMS on square microstructures, fabricated by photolithography (Lee et al., 2007; Shih et 
al., 2006). In 2012, De Ville and co-workers used the surface tension of alginic acid sodium 
salt solution inside square microchannels, so that such liquid creates rounded protrusions 
(De Ville et al., 2012); it is a simple and low-cost method for the fabrication of round 
PDMS microfluidic channels but it lacks the capability to easily tune curvature; no circular 
microchannels could in fact be obtained. To the best of our knowledge, an easy, low cost 
and versatile method to fabricate circular microchannels is therefore still missing. In this 
paper, we present an innovative fabrication method that combines spin coating and 
micromilled square microchannels to fabricate circular microchannels ensuring easy and 
low cost manufacturing that can be applied without the need for clean room facilities. In 
this process centrifugal forces and surface tension cause together the localization of the 
liquid PDMS in the corners of the channel providing the desired curvature. We demonstrate 
that -by tuning parameters such as viscosity, geometry of the starting square channel, spin 
coating speed- it is possible to obtain circular and, more in general, round-shape and closed 
microchannels. The geometry and quality of the semi-circular PDMS channels created by 
spin coating technology was characterized using optical microscopy, scanning electron 
microscopy (SEM) and a surface profilometer, while AFM was used to characterize 
channel roughness. The versatility of this method was further demonstrated by proving the 
possibility to produce hybrid solutions and rounded microchannels different from circular 
ones. Finally, preliminary experiments on brain endothelial bEnd.3 cells indicate the 
capability of the circular microchannels to allow a good adhesion, an improved growth and 
a more homogeneous distribution of the cells over the surface of the channel than those 
obtained with the square microchannel of comparable size used as a control.  
 
4.3 RESULTS AND DISCUSSION 
 
Motivated by the strong need in the microfluidic fields for circular microchannels, we 
propose an innovative hybrid technique that combines mechanical micromachining and 
spin coating process which is easy, reproducible and cost-effective. The process used to 
fabricate semi-circular microchannels is schematically outlined in Fig. 1.  
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Figure 1: Scheme of the spin coating process (a). Picture of a 800 x 400 µm PMMA 
microchannel before and after spin coating, respectively (b and c). The PDMS adhering to 
the microchannel wall after spin coating and consolidation by thermal curing. 
In particular, a mixture of PDMS precursor and curing agent is dispensed on the square 
microchannel obtained by micromilling followed by the spin coating process. The 
deposited liquid layer under spin coating is able to form a stable rounded PDMS layer on 
the walls of the square microchannel. Such rounded microchannel can be consolidated by 
curing the PDMS. Using undiluted PDMS solution, a PDMS circular shape in the square 
microchannel 800 x 400 µm was observed at around 2000 rpm and 20 s. In particular, Fig. 
1c displays the PDMS adhering to the microchannel wall after spin coating and thermal 
curing. Undiluted PDMS proved too viscous to obtain a circular section in the case of 
narrower microchannels, independently of the spinning conditions; we used a mixture of 
PDMS and hexane at a ratio optimized according to each microchannel size in order to 
lower viscosity. Table 1 reports the degrees of dilutions capable to provide circular shapes 
at 2000 rpm and 20 s of spin coating in the differently sized microchannels and the 
corresponding viscosities.  
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Table 1: Viscosity of the different PDMS solutions and corresponding circular 
microchannel diameters, measured using a Modular Compact Rheometer (Anton Paar). 
 
In particular, the smaller the microchannels, the lower the viscosity used. From this table 
and related graph, it is possible to appreciate that reducing the size of the microchannels, 
dilution is less and less influent such that a semi-circular microchannel of 50 µm could be 
obtained with the same degree of dilution as the 100 µm microchannel. All the semi-
circular shapes observed by SEM are summarized in Fig. 2. 
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Figure 2: SEM images of semi-circular PDMS positive relief replicas (a-d), the 
corresponding semi-circular PDMS microchannels (e-h) and cross-section of bonded 
circular microchannels (i-n). The microchannels have diameters of 800, 400, 200 and 100 
µm, respectively. 
 
 From the SEM micrographs it is possible to note the possibility to scale down the method 
in terms of microchannel size to around 50 µm. Circular shapes are evident from the SEM 
cross-section of closed microchannels (Fig. 2 i-n). In order to better characterize the 
uniformity of the microchannels along their extension and the reproducibility of the 
process, PDMS replicas made directly from the PMMA-PDMS masters (800/400 µm 
width/depth) were measured by using a profilometer (figure S1 and S2 in Supplementary 
Data). For the profilometer characterization we used a map scan type on hills profile, a 
stylus type radius of 2.5 µm and a measurement range of 525 µm. Other studies have 
investigated the use of spin coating technology to fabricate ultrathin and hyperelastic 
PDMS nano-membranes with various thicknesses and sizes by using PDMS diluted with 
hexane (Thangawng et al., 2007). Herein, for the first time we have applied the thinning 
property of the PDMS-hexane mixture for scaling down, below 800 µm, the manufacturing 
of circular microchannels starting from cost-effective square PMMA microchannels. 
Circular microchannels can also be fabricated by micromachining a substrate with tapered 
angle ball tips. We made a comparison between surfaces obtained with our method and 
with direct channel fabrication by micromilling. From the optical microscope images (Fig. 
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3a,b) it was possible to observe the absence of the engraving line in the case of the mold 
prepared with our method with an increase of the transparency. Moreover, roughness 
profiles were characterized by AFM showing an enhancement of the smoothness since it 
was  ̴ 228 nm compared to   ̴6 nm (Fig. S3).  
 
 
 
 
 
 
Figure 3: A bright field microscopy image of semi-circular PDMS microchannels, 
replicated directly from a micromilled round microchannel (a) and from a semi-circular 
microchannel obtained using the proposed method (b). 
 
This huge reduction in terms of roughness is highly desirable in microfluidics as previously 
mentioned and it is also advantageous from an optical standpoint since the final 
microchannel results much more transparent and internally inspectable. 
To produce closed microchannels, after fabricating the two symmetric semi-circular 
microchannels we treated their surface by oxygen plasma so that they could irreversibly be 
bonded after alignment (Fig. 2i-2n). They are examples of closed microchannels of very 
different sizes ranging from 800 to 100 µm. For the small microchannels the alignment was 
carried out by using motorized stages coupled with an optical camera (Fig. S3). As 
anticipated in the introduction, our method can also allow the fabrication of a hybrid 
PMMA-PDMS device where two symmetric PMMA-PDMS semi-circular microchannels 
obtained after PDMS spin coating on square microchannels in PMMA can be directly 
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bonded, instead of acting as masters. In this case, by using small magnets embedded into 
the PMMA substrates it is possible to easily align even the smallest microchannels (down 
to 50 µm) -as shown in Fig. 4a- avoiding motorized stages. 
 
 
 
 
 
 
 
 
Figure 4: A hybrid modular device made of PMMA and PDMS with neodymium magnets, 
a microchannel section SEM image (a). Branched and curved semi-circular PDMS 
microchannels, emulating arterioles and venules (b). A ring-shape microchannel obtained 
from a square geometry (c). 
 
 
 With a hybrid device it is possible to combine the rigidity of the PMMA useful in the 
handling of the device -for example during the alignment step- with the softness and the 
low roughness of the spin coated PDMS. In addition, the PDMS layer in the case of 
magnetic bonding provides a strong sealing making temporary bonding with no leakage 
(Supplementary data in Fig. S5 a) 
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Figure 5: bEnd.3 cell growth in square (a and c) and circular (b and d) microchannels 
(width: 400 µm) after 24 (a and b) and 72 (c and d) hours. Blue represents cell nuclei 
stained with DAPI. Green represents actin microfilaments stained with 488Alexa-
phalloidin. Merge is the overlapping of the blue and green channels. Z-sec is the projection 
along z-axis of confocal z-sectioning images (z-slice thickness = 1.28 µm, number of slices 
= 162). Scale bar 100 µm. 
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PDMS is also useful as an optimal interface for cell cultures. A recently proposed method 
to fabricate circular microchannels is based on the use of compressed air injected in a 
square microchannel filled with PDMS precursor. Despite the advantage to avoid any 
alignment, air pressurized technology cannot be applied to branched microchannels. 
Moreover, the gradient pressure inside the microchannel may prevent a uniform thickness 
of the PDMS around the wall, especially in the case of microchannels curved in plane. Our 
technique, instead, allows preparing branched microchannels as shown in Fig. 4b, useful to 
emulate arterioles and venules with the same principle of single microchannels and 
microchannels curved in plane as shown with ring-shape microchannels in Fig. 4c and S5 b. 
In addition, with the proposed method all the structures can be inspected before bonding 
thanks to the starting open microchannels and the vertical curvature of the final 
microchannel can be tuned. In particular, as described in the experimental section, to obtain 
semi-circular shapes we used in all cases a width twice long as the depth of the square 
microchannel, while to tune the curvature of the final microchannel we were able to vary 
the depth of the square microchannel (Fig. S6). Another recent work is based on the filling 
of square microchannels exploiting surface tension, which creates protruding round liquid 
to be replicated after consolidation. Although it does not involve expensive equipment for 
the fabrication, it is limited in the tuning of the curvature and in the production of discrete 
microchannels because of filling issues; therefore, circular microchannels were not 
obtained. In terms of flexibility other parameters that can be exploited with our method for 
the tuning of the curvature are viscosity (especially in the case of large widths) and spin 
coating speed.  
Moreover, we preliminarily tested the potential applicability of the as-prepared circular 
microchannels to sustain growth and formation of a confluent endothelium in vitro. To this 
aim, brain endothelial bEnd.3 cells were seeded inside a 400 µm-diameter circular 
microchannel and cultured for 24 and 72 h. We chose to work with brain endothelial cells 
as a model of endothelial tissue and, in particular, of the blood brain barrier that currently 
represents one of the main goals of many therapeutic strategies and biomedical applications 
(Guarnieri et al., 2013; Kreuter, 2001). As shown in Fig. 5, bEnd.3 cells were able to 
adhere and grow into the circular microchannels. In particular, after 72 h of culture, cells 
formed a confluent and very homogeneous monolayer that resembled the endothelial tissue. 
Conversely, when cultured into a 400 µm wide square microchannel, cell adhesion, 
spreading and proliferation were less efficient. More interestingly, the distribution of the 
cells along the square microchannel was not homogeneous. In particular, we observed a 
high cell adhesion in the middle of the channel and a poor adhesion in the corners. These 
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observations were more evident at a longer culture time (72 h) and were in agreement with 
previously reported results (Farcas et al., 2009; Jang et al., 2015). We quantified the cell 
density over time in both microchannel shapes. As shown in Fig 6, this analysis shows a 
higher cell number per mm
2
 in the circular microchannel compared to the square 
microchannel. 
 
Figure 6: Analysis of cell density in the square and circular microchannels at 24 and 72 h of 
culture by Image J software. 
 
Taken altogether, these data demonstrate the advantage of our circular microchannels in 
culturing endothelial cells compared to channels with squared geometry and their potential 
use as scaffolds able to promote the formation of brain capillary-like structures.  
4.4 MATERIALS AND METHODS 
 
The poly(methyl methacrylate) PMMA substrates used in this study, thickness 1.2 mm, 
were purchased from Goodfellow Cambridge Ltd, (UK) and belong to the same batch of 
supplied PMMA substrates. PMMA offers several material properties including optical 
transparency, low cost, inexpensive manufacturability, possibility of chemical 
treatment and biocompatibility. A PDMS prepolymer and a curing agent (Sylgard 184 
elastomer kit) were purchased from Dow Corning Corporation (USA). Hexane puriss. p.a. 
was obtained from Sigma-Aldrich, (USA). The microtools used in the microfabrication 
process were 5 tr series 2 flute micro square end mills with different diameters: 800, 400, 
200, 100 and 50 μm and 1 tr series 2 flute micro ball end mill with a diameter of 800 μm; 
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they were purchased from Performance Micro tool (USA). Micromilling machine was 
purchased from Minitech Machinery Corporation (USA). Syringe pump 11 Helite Series 
was purchased from Harvard apparatus (USA). Fabricated microchannels were inspected by 
electron scanning microscopy (SEM) (Ultraplus Zeiss) and profilometer (Veeco Dektat 
150). For the spin coating process, a spin coater from Laurell (WS-650 Series) was used. 
Mouse cerebral endothelial cells, bEnd.3 cells, were purchased from American Type 
Culture Collection, Manassas, VA. Dulbecco’s Modified Eagle’s Medium (DMEM) with 
high glucose, trypsin, Dulbecco’s phosphate-buffered saline (DPBS), fetal bovine serum 
(FBS), penicillin and streptomycin were purchased from Gibco Invitrogen, USA. Sodium 
pyruvate and DAPI were purchased from Sigma-Aldrich, (USA). Glutamine was purchased 
from Lonza Group Ltd,Basel, Switzerland. Non-essential amino acids were purchased from 
EuroClone S.p.A., Milano, Italia. Red fluorescent WGA and Alexa488-phalloidin were 
from Gibco Invitrogen, USA. 
 
4.4.1 Square microchannels fabrication 
 
The square microchannels were typically fabricated by sequentially micromachining 
PMMA layers by using the above mentioned micromilling machine. Milling is a subtractive 
microfabricating process that uses rotating cutting tools to remove material from a substrate 
(Chen et al., 2014; Dornfeld et al., 2006; Guckenberger et al., 2015). To standardize the 
fabrication process of semi-circular microchannels from square geometry, we micromilled 
microchannels with different width-depth: 800-400, 400-200, 200-100, 100-50 and 50-25 
µm. Different ratios of width-depth, such as 800-300 and  400-100 µm, were also used to 
show capability of tuning the curvature of the final rounded microchannels. Moreover, to 
show the versatility of this method -by using a 400 µm end mill- we micromilled 
microchannels with branches that emulate arterioles and venules, as well as ring-shape 
microchannels. To design a draft of the microstructures we created a layout by Draftsight 
(Cad Software). During micromilling, spindle speed, feed speed and plunge rate per pass 
were set to 10 000 rpm, 15 mm s
-1
, and 20, respectively.  
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4.4.2 Spin coating and fabrication of circular PDMS microchannels 
 
Spin coating is a common technology for the production of polymer films of controlled and 
uniform thickness (Koschwanez et al., 2009; Mata et al., 2005). To create semi-circular 
microchannels of different diameters from square microchannels we used the above 
mentioned spin coater. A typical process involved depositing a small PDMS droplet, mixed 
in ratio 10:1 with curing agent, (around 1 ml) at different degrees of dilution with hexane 
onto the center of a substrate and then spinning at high speed (2000 rpm for 20 s). PDMS 
precursor was previously exposed to vacuum to eliminate air bubbles for at least 30 min. 
The PMMA-PDMS with round open microchannels was baked in the oven (1 h, 75 °C), to 
finalize the PDMS curing process. PDMS solution was poured on the hybrid PMMA-
PDMS master and cured at 80 °C for 2 h. Particularly, in order to prevent adhesion of the 
PDMS replicas on the master, this was treated with oxygen plasma to activate the surface 
using a plasma chamber (Plasma prep II, SPI) for 1 min at a pressure of 0.3 mbar and 
power of 37 W, immersed for about 2 min into a silane solution (i.e., a mixture of 94% v/v 
isopropanol (Sigma Aldrich), 1% acetic acid (Sigma Aldrich), 1% Fluorolink S10 (Solvay), 
and 4% deionized water and then placed in an oven at 75 °C for 1 h, thus allowing a 
complete reaction of the master surface with the fluorinated polymer (Occhipinti, 2010). 
After curing, the PDMS was peeled off from the PMMA-PDMS master. The entire 
procedure was repeated to prepare final PDMS open microchannels (Brittain et al., 1998; 
Xia and Whitesides, 1998). In the case of closed microchannels, two symmetric semi-
circular microchannels were optically aligned and bonded through oxygen plasma 
activation of the surface. For the very small microchannels the alignment was aided by the 
use of two parallel motorized stages coupled with an optical camera. Temporary bonding 
was also carried out by using magnets with the advantage of obtaining high precision 
alignment avoiding motorized stages and the possibility to reopen closed microchannels 
after use. 
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4.4.3 Brain endothelial cell seeding and growth within square and circular 
microchannels 
 
The fabricated open microchannels (400/200 µm width-depth), were bonded to a glass slide 
through oxygen plasma activation; closed microchannels were sterilized with 10 % 
penicillin-streptomycin solution in PBS before cell seeding for 24 h at 4 °C to prevent 
contamination. Both square and circular microchannels were coated with 10 µg/ml 
fibronectin (Sigma-Aldrich) for 1 h at 37 °C. Afterwards, the microchannels were washed 
with PBS to remove fibronectin excess. bEnd.3 cell suspension, at a density of 6 × 10
5
 
cells/ml, were injected into the channels. After incubation for 20 min in a 5 % humidified 
CO2 incubator at 37 °C for cell attachment, bEnd.3 were reseeded within microchannels 
and incubated again, rotating the devices by 90° as previously described. (Farcas et al., 
2009; Jang et al., 2015) This step was repeated three more times to cover the entire surface 
of the circular and square microchannels. Then, cells were allowed to grow for 24 and 72 h 
within the channels. At these time points, cells were fixed with paraformaldehyde 4% for 
10 min and actin microfilaments and nuclei were stained with Alexa488-phalloidin 
(Molecular Probes) and DAPI (Sigma). Samples were observed and images were acquired 
by multiphoton confocal microscope (Leica TCS SP5 MP) equipped with a 20 × dry 
objective. Z-sectioning images were acquired with 1.28 µm z-slice thickness. Cell density 
was calculated normalizing the number of nuclei for the area of the channels by Image J 
analysis software. 
 
4.5 CONCLUSIONS  
 
We developed a fast and reproducible method to fabricate polymeric circular microchannels 
from micromilled square microchannels coupling a spin coating technology. In particular, a 
PMDS precursor was deposited by spin coating on the square microchannels and formed a 
circular shape thanks to surface tension, which smoothed the corners. This PMMA-PDMS 
master was then used to prepare final semi-circular microchannels by double replica of 
PDMS, which can be aligned and bonded when closed microchannels are required. This 
process was useful in making small circular microchannels (down to 50 µm) and it also 
showed to be effective in creating microchannels with a branched and a ring-shape 
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geometry. Therefore, we propose a reproducible, versatile, and low cost method to produce 
open or closed circular microchannels for in vitro vascular microcapillaries that is also 
useful for other applications such as plug production and microparticle alignment. As a 
proof of the advantage of producing circular rather than square microchannels, we cultured 
cells in both devices and verified how the presence of corners negatively affects the growth 
and uniformity of an endothelial cell layer. Results support the conclusion that cylindrical 
microchannels are more appropriate for cell growth, particularly when an in vivo system 
needs to be mimiched in vitro. 
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5 CHAPTER 4  
 
Effect of flow conditions on shuttle-mediated nanoparticle transport across the brain 
endothelium 
 
5.1 ABSTRACT 
In the last few years, several in vitro studies have been developed in order to address some 
of the fundamental mechanisms involved in BBB crossing by solutes, drugs and 
nanoparticles 
1
. Indeed, except their comparatively high permeability and the loss of 
expression of some BBB efflux protein systems, in vitro models have several advantages 
over in vivo models, including low cost, high throughput screening and easiness to assess 
compounds and to investigate the transport mechanism at the molecular levels. 
Development of a rapid and reliable in vitro BBB model system is a challenge to reveal the 
drug delivery to the central nervous system (CNS). It is fundamental to test the efficacy on 
targeting and crossing of nanocarriers inside in vitro models which are able to mimic in 
vivo characteristics of the BBB. To this aim, a BBB microfluidic device was designed 
based on a transparent polyester porous membrane sandwiched between a top and a bottom 
overlying channel made of PMMA. Our data clearly indicate that this microfluidic system 
allows the growth of brain endothelial bEnd.3 cells and the formation of a confluent layer. 
Expression of the barrier properties was tested with trans-endothelial electrical resistance 
(TEER). By day 3 of cell culture TEER levels exceeded 100 Ω cm2 reaching a plateau at 
day 7.  Confocal images confirmed the expression of tight junctions. BBB monolayer 
regulates the selective transport of albumin and nanoparticles compared to blank porous 
filter. More interestingly, the decoration with gH625 peptide enhances the adhesion of 
nanoparticles at the endothelial layer and the BBB crossing at 5 µl/min flow rate, thus 
suggesting the efficacy of gH625 as a delivery platform to the brain. Here, we demonstrate 
for the first time the ability of a membranotropic peptide, namely gH625, to transport a 
cargo across the BBB layer under flow conditions 
2
. 
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5.2 INTRODUCTION 
The blood-brain barrier (BBB), with its distinctive tissue structure, acts to separate the 
peripheral blood from the central nervous system (CNS), thereby maintaining brain 
homeostasis 
3
. Among other things, the permeability of the BBB is controlled by the brain 
endothelial cells, that regulate the selective transport from the blood to the brain and vice 
versa 
4
. The endothelial layer is also essential in preventing the entrance of toxic substances 
to the brain. Indeed, due to this tight barrier, the majority of drugs fail to cross the BBB. 
The BBB represents the main challenge for the development of new drug delivery systems, 
and many strategies are currently under development to improve the uptake of therapeutic 
compounds into brain parenchyma. Among other things, it has been recently demonstrated 
that the conjugation with the membranotropic peptide gH625 facilitates the delivery of 
nanoparticles across the BBB, leading to a significantly higher cell uptake and crossing, 
and, most importantly, to a reduction of NP intracellular accumulation as large aggregates 
in a static BBB model 
5
. gH625 belongs to a class of hydrophobic peptides that efficiently 
traverse biological membranes promoting lipid membrane-reorganizing processes, such as 
fusion or pore formation, thus involving temporary membrane destabilization and 
subsequent reorganization 
6
. These molecules are currently obtaining great attention since 
those may be exploited for drug delivery purposes 
7,8
. In particular, the nineteen-residue 
peptide gH625 is a membrane-perturbing domain derived from the glycoprotein H (gH) of 
Herpes simplex virus 1; it interacts with model membranes, contributing to their merging  
and is able to traverse the membrane bilayer and transport a cargo into the cytoplasm and 
across the BBB in vitro 
9,10
. Nowadays, most of BBB experiments are performed in static 
Transwell assays 
11–13
. However, in vivo brain endothelial cells are subjected to the blood 
flow that lacks in the commonly used in vitro models. In this context, in vivo models are the 
best candidates to study the transport across the BBB. However, these resources are scarce, 
expensive and difficult to study both in detail and real-time. Ex vivo and in vitro models are 
good alternatives, as they are credited for their simplicity and controlled environment 
4
. 
Moreover, shear stress derived from blood flow positively affects endothelial cell 
physiology and tight junction formation 
14
. Till now, there are only few papers published of 
a dynamic BBB model 
15–18
. Recently, the use of micro-technologies to study organ 
physiology has received rapidly growing attention (Huh et al. 2011). These organs-on-chips 
have the potential to be used as human-relevant disease models, and additionally provide 
detailed insight into drug effects 
14,19
. Two microfluidic models of the BBB have recently 
been reported, demonstrating the feasibility of an organ-on-chip approach 
15,16
. The aim of 
this work has been to test the ability of gH625 peptide to transport nanoparticles across the 
 
84 
 
brain endothelium under flow conditions. To mimic the blood flow in brain capillaries, we 
designed an in vitro µ-fluidic BBB model. The system was realized in such a way as to 
permit the growth of the cells on a porous filter up to reaching the confluence and to 
separate two compartments delimited by endothelial layer, namely the blood side and the 
brain side. The microfluidic chip (Fig. 1) contains a transparent polyester microporous 
membrane (Corning Costar, Cambridge, MA,USA) sandwiched between a top and a bottom 
overlying channel. The endothelial layer is obtained on the porous membrane directly into 
the device after culturing mouse brain endothelial cells. A collecting chamber is also 
integrated on the top channel in order to collect traversed NPs. To verify our issue, we first 
characterize the growth and the formation of a confluent brain endothelial layer of bEnd.3 
cells within the in vitro µ-fluidic system through bright-field and confocal microscopy 
observations. Then, the permeability of this system was tested by using fluorescent albumin 
(BSA) as a standard molecule and amine-modified fluorescent polystyrene nanoparticles as 
a control indicating the functionality of our model. Finally, the capability of gH625-
conjugated nanoparticles to adhere to and cross the brain endothelial layer under flow 
conditions were investigated. 
 
 
 
Figure 1. Scheme of the developed BBB microfluidic system (A), including (1) the bottom 
channel, (2) polyester membrane, (3) the top channel, (4) the Nanoport UPCHURCH® 
connectors and (5) collecting chamber. Picture of the fabricated chip (B) and SEM image of 
a section of the device (C). 
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5.3 RESULTS AND DISCUSSION 
 
5.3.1 In vitro BBB model characterization 
 
The microfluidic device was tested before cell seeding in terms of sealing. It was also 
morphologically characterized by SEM in order to confirm the right alignment and 
dimensions of the channels (Fig. 1 C).  
bEnd.3 cells were seeded in the channel and allowed to adhere to the membrane for 24 h at 
37 °C. Afterward, the system has been turned upside down, the channel was rinsed with 
fresh medium to remove non-adhered cells and incubated at 37 °C for 1, 3 and 7 days of 
culture. Fig. 2 shows phase contrast images of bEnd.3 cell layer after different days of 
growth in the microfluidic device.  
 
Figure 2. Phase contrast microscopy pictures of endothelial cell layer in the microfluidic 
system channel after 1 (A), 3 (B) and 7 (C) days from cell seeding. Bar 100 µm. 
 
 
86 
 
As reported, cell confluency increased over time. After 7 days post cell seeding, the cells 
formed a confluent monolayer as demonstrated by the nuclei and microfilament fluorescent 
staining (Figs. 3 A-C). Image analyses confirmed that the cell density per area increased 
over time (Fig. 3 G). To verify the formation of tight junctions, indirect 
immunofluorescence against Claudin 5 protein was performed at the 7
th
 day of culture. 
Confocal microscopy images show that bEnd.3 cells were able to express Claudin 5 
protein, prevalently localized around the cell boundaries thus indicating the formation of 
tight junctions (Fig. 3 H). These data demonstrate the capability of the microfluidic device 
to allow the growth and the correct formation of the confluent brain endothelial layer. 
 
 
Figure 3. 7-day growth confluent bEnd.3 cell layer. (A, D) Phalloidin (red) staining of 
cytoskeleton; (B, E) DAPI (blue) staining of nuclei; (C, F) bright-field images of the 
polyester filter. (A-C) Images acquisition performed with a 10 × dry objective. (D-F) 
Zoomed images shown in panels (A-C). (G) Cell density over culture time. (H) Claudin 5 
(green) and DAPI (blue) staining of tight junctions and nuclei, respectively, acquired with a 
25 × water-immersion objective. Bar 50 µm. 
 
87 
 
 
5.3.2 TEER measurement 
 
TEER was measured every day after seeding in order to monitor cell confluence and the 
development of tight junctions. TEER results indicated high 
16
 resistance value for BBB 
microfluidic model (Fig. 4). Our cultures reached the steady-state by day 5-7. TEER level 
remains of 110 Ω cm2 at day 7 of culture, according with the Claudin-5 imaging data. 
Therefore day 7 was chosen as endpoint threshold for transport assays.  
 
Figure 4: TEER measurements over culture time. 
 
5.3.3 BSA transport across the BBB 
 
In order to assess the integrity of the cellular monolayer, we performed transcytosis 
experiments to test the capability of BSA to cross the endothelial layer. BSA is known to 
cross the BBB through adsorptive transcytosis, therefore it can be used as a valid standard 
to measure the system functionality under flow conditions 
20,21
. BSA transport experiments 
were performed after 7 days of cell culture under static conditions. The device was 
connected to a syringe pump and the cells were subjected to a flow rate of 5 µl/min which 
follows in the typical range of flow rates reported in literature 
22,23
. Fig. 4 shows the mass of 
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the transported BSA across the microfluidic system at regular time points. In absence of the 
cells, almost 100 % of BSA was transported after 3h. Conversely, in the presence of the 
confluent cell layer, there was a significant decrease in the BSA permeation, with about 16 
% of transported BSA after 3 h under flow conditions.  
. 
 
Figure 4. Mass of transported BSA under flow conditions, flow rate: 5 µl/min in absence 
and in presence of the confluent cell layer 
 
5.3.4 Nanoparticle transport across the BBB in the microfluidic system 
 
In order to validate the BBB microfluidic device for nanoparticle transport studies, NP 
transcytosis experiments have been performed, both in presence and in absence of the 
confluent cell layer at two different flow rates (5 and 25 µl/min) for 3h. Experiments were 
carried out by diluting NPs at a concentration of 9.20 × 10
10 
NP/ml in buffered cell culture 
medium. As shown in Fig. 6, in presence of the blank filter membrane the percentage of the 
transported NPs through the BBB monolayer at 5 µl/min was about 7 times higher than the 
transported NPs at 25 µl/min. More precisely, it was 13.45 % at 5 µl/min and 1.96 % at 25 
µl/min. In presence of the confluent cell layer, the trend was inverted and the percentage of 
transported NPs decreased. In particular, the percentage of transported NPs at 5 µl/min was 
2.72 % against 7.33 % found at 25 µl/min.  
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Figure 6. Percentages of transported blank NPs under flow conditions in absence (A) and 
in presence (B) of the confluent cell layer. Data are reported at two different flow rates, 5 
and 25 µl/min. Percentages of transported blank NPs under flow conditions (Flow rate: 5 
µl/min), in absence and in presence of the confluent cell layer (C). D and E represent 
confocal images of blank NPs in bEnd.3 cells after 3 hours of experiment in flow condition. 
Green: blank NPs; blue: nuclei. Bar: 10 µm. 
 
We hypothesized that these results could depend on a breakage of the endothelial layer as a 
result of the combination of high flow rate and high NP concentration. Therefore, in order 
to understand the effect of the NP concentration on the integrity of the cell monolayer, we 
performed the transcytosis experiment at the higher flow rate (25 µl/min), by using a NP 
suspension at a concentration - 1.84 x 10
10
 NP/ml - 5 times lower than the previous 
experiments. Results shown in Fig. 7A indicate that after 3h under flow conditions, the 
percentage of transported NPs was 9.90 % with the filter alone, decreasing to 3.44 % in 
presence of the layer. In these conditions, we obtained results quite similar to those 
obtained at a fivefold lower flow rate (5 µl/min) with a fivefold higher NP concentration 
(9.20 × 10
10 
NP/ml). In fact we obtained 4.84 % of transported NPs at 25 µl/min by using 
NP concentration of 1.84 x 10
10
 NP/ml and 2.72 % at 5 µl/min by using 9.20 × 10
10 
NP/ml, 
in presence of the monolayer (Fig. 7B). 
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Figure 7. Percentages of transported blank NPs under flow rate of 25 µl/min at a final 
concentration of 1.84 × 10
10
 NP/ml (A). Data are reported in absence and in presence of the 
confluent cell layer. Blank NPs under flow rates of 5 and 25 µl/min, at final concentrations 
of 9.20 × 10
10
 and 1.84 × 10
10
 NP/ml, respectively, in presence of the monolayer (B).  
 
Taken altogether these findings indicate that: i) the presence of the layer hinders the 
passage of solutes and nanoparticles across the filter; ii) the integrity of the cell layer 
depends on a right combination between the concentration of the nanoparticles and the flow 
rate.  
5.3.5 Effect of the functionalization with gH625 peptide on nanoparticle transport 
across the BBB in the microfluidic system 
 
Several works reported that NPs enter the cells using a cell-mediated mechanism, called 
endocytosis. After endocytosis, endosomes can deliver their cargo across the cell by 
transcytosis processes. Alternatively, these vesicles can also be sent to the lysosomes for 
degradation. It was previously demonstrated that gH625 is able to transport different cargos 
such as liposomes and quantum dots across cells 
10,24,25
. In a previous work, the surface of 
fluorescent aminated polystyrene NPs has been functionalized with gH625 and transport 
across static in vitro BBB models has been investigated. Results demonstrated that gH625 
NPs translocate efﬁciently across cell membranes and cell internalization does not seem to 
exclusively involve classical endocytosis mechanisms. In fact, conjugation with gH625 
facilitates the delivery of nanoparticles across the BBB, leading to signiﬁcant higher cell 
uptake and crossing, decreasing lysosomal accumulation 
5
. Based on the previous 
observations, we tested the capability of gH625 to enhance NP transport across the BBB 
layer in flow conditions, using 5 µl/min flow rate and a NP concentration of 9.20 × 10
10 
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NP/ml. Fig. 8 A shows the comparison of the transported blank and gH625-NPs. As 
reported, gH625 increases about two fold the transport of NPs through the BBB, becoming 
6.13 % compared to 2.72 % of non-functionalized NPs. Looking at the cell layer, we 
observed the adhesion of blank and gH625-nanoparticles after the flow experiments (Figs. 
8 B-E). Data of image fluorescent analysis show an increment of about two fold of adhered 
gH625-NPs compared to blank NPs (Fig. 8 F) thus indicating an affinity of functionalized 
nanoparticles to the cell membrane higher than the blank ones in dynamic conditions. 
Actually, gH625 peptide shows a particular tropism for cell membrane cholesterol 
26
. It is 
likely that this property may promote the interaction of gH625 functionalized nanoparticles 
with the cells and, as a consequence, their adhesion on the cell membrane also in flow 
conditions. 
 
 
Figure 8. Blank and gH625-NPs (A) transported under dynamic conditions (Flow rate: 5 
µl/min). Confocal images of the confluent cell layer in the µ-fluidic system after the 
experiment: green fluorescent represents blank NPs (B) and gH625-NPs (C). D and E are 
merge images of red Phalloidin and blue nuclei with blank NPs and gH625-NPs, 
respectively. Percentages of blank and gH625-NPs per image area (F). The data are 
reported as the mean ± SD (n = 5), *** P < 0.0001.  Bar 50 µm. 
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5.4 MATERIALS AND METHODS 
5.4.1 Microfluidic system design and fabrication 
 
In this section, we detail the design and fabrication of the microfluidic chip. It is based on 
different PMMA layers bonded via solvent evaporation. Specifically, the assembly of the 
PMMA layers was performed by simply immersing PMMA substrates in ethanol for 10 
min. The immersed substrates were immediately removed, aligned and clamped for an 
overlap of the top and bottom channel, after the heat treatment was initiated at 58 °C for 45 
minutes. Before proceeding with the assembly of the chip the manufacturing substrates 
were cleaned using a common soap (RBS Ditalclean, Brussels). The bonding between the 
top and the bottom channel substrates allows to enclose the polyester membrane on which 
cells are grown afterwards. PMMA is a transparent thermoplastic polymer that can be 
easily micro-machined by micromilling (Minitech Machinery Corporation) which is a fast 
prototype technique. (P. C. Chen, C. W. Pan, W. C. Lee and K. M. Li, International 
Journal of Advanced Manufacturing Technology, 2014, 71, 1623-1630). In addition to bond 
NanoPorts Upchurch® to PMMA microdevices, we developed a hybrid system, which 
glues commercial nano-ports with an alternative biocompatible epoxy adhesive. The 
microfluidic chip shown in Fig. 1 is composed of two PMMA channel substrates (12 x 50 x 
1 mm) and a PMMA collecting chamber (12 x 30 x 1 mm). The depth and width of the 
channel is different onto the two PMMA substrates, 889 µm width and depth for the bottom 
channel and 1.2 mm of depth and 889 µm of width for the top channel. The microtool used 
to micromachine the PMMA was in all the cases a flute endmill with a 889 µm in diameter. 
In the second PMMA layer we microfabricated inlet and outlet holes to connect 
microfluidics chip with classic fluidic equipment such as syringe pump and tubing. The 
fabrication process consists of 4 steps: (1) preparation of the chip draft using Draftsight 
(Cad Software), (2) micromachining of PMMA layers; (3) ethanol-assisted bonding process 
and (4) bonding Nanoport Upchurch to PMMA substrate. The certified positioning 
accuracy of the three-axis are 12”/300 mm in x-axis, 9”/228 mm in y-axis, and 9”/228 mm 
in z-axis. To standardize the fabrication process, the PMMA substrates used in this study 
were purchased from the same batch of the polymer supplier (GoodFellow Cambridge 
Limited, England).  
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5.4.2 Cell culture 
 
Mouse cerebral endothelial bEnd.3 cells (American Type Culture Collection, Manassas, 
VA) were grown in DMEM with 4.5 g/L glucose, 10% Foetal Bovine Serum (FBS), 3.7 g/L 
sodium bicarbonate, and 4 mM glutamine, 1% non-essential amino acids, 100 U/ml 
penicillin and 0.1 mg/ml streptomycin in 100 mm diameter cell culture dish, in a 
humidified atmosphere at 37 °C and 5% CO2. Cells used in all experiments were at passage 
11–18. 
5.4.3 Fluorescent solutes and nanoparticles 
 
Fluorescein isothiocyanate conjugated bovine serum albumin (FITC-BSA, MW 66 kDa) 
and orange fluorescent amine-modified polystyrene, 100 nm, nanoparticles (NPs) were 
purchased by Sigma-Aldrich. 
5.4.4 gH625 peptide synthesis and conjugation to polystyrene nanoparticles 
 
gH625 peptide (Ac-HGLASTLTRWAHYNALIRAFGGG-COOH) was synthesized using 
the standard solid-phase-9-fluorenylmethoxycarbonyl (Fmoc) method as previously 
reported [17] and obtained with good yields (30 - 40 %). The conjugation of gH625 to 
amine-modified fluorescent polystyrene nanoparticles was performed as described 
previously [21]. Briefly, the peptide was preactivated with EDC (1-Ethyl-3(3-
dimethylamino-propyl)-carbodiimide, hydrochloride) and NHS (N-Hydroxysuccinimide) in 
molar ratio of 4:4:1 in PBS buffer at pH 7.4, at room temperature (RT) under stirring for 30 
min. NPs were conjugated with the preactivated-peptide, in MES 0.1 M buffer at pH 5.5 for 
3 h at RT in presence of Tween 20 and the yield of the reaction was higher than 90 %. The 
peptide-NPs were purified from the unconjugated-NPs by exclusion chromatography on a 1 
× 18 cm Sephadex G-50 (Amersham Biosciences) column. The fluorescence spectra of 
peptide-NPs and unconjugated NPs were measured in a Cary Eclipse Varian fluorescence 
spectrophotometer. 
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5.4.5 Cell seeding and culture in the microfluidic system 
 
The fabricated chip was previously sterilized with 10 % Penicillin-Streptomycin solution 
for 24 h at 4 °C to prevent contamination. bEnd.3 cells were seeded at a density of 25 × 10
3
 
cells/cm
2
 into microfluidic channel and the system was turned upside down, in order to 
allow cell adhesion to the polyester filter located on the top of the channel. Non-adhered 
cells were removed 24 h after seeding by twice washing with fresh cell culture medium. 
Afterward, cells were allowed to grow until 7 days within the device. Medium was 
refreshed every 3 days. Cell growth was monitored over time by phase contrast and 
confocal microscopy at 1, 3, 5 and 7 days of culture. In order to further verify cell growth in 
the microfluidic system, bEnd.3 were fixed within system with 4 % paraformaldehyde for 
10 min at RT and stained with 4, 6-diamidino-2-phenylindole (DAPI, Sigma), hence, the 
number of nuclei was counted by imageJ software 1.44p.  
5.4.6 Cell staining 
 
The presence of tight junctions was determined by immune-staining with anti-Claudin 5 
antibody (Life Technologies). Briefly, bEnd.3 cells were fixed with 4% paraformaldehyde 
for 10 minutes. After permeabilization with 0.1 % Triton-X100, cells were incubated with 
the blocking buffer (BB) (0.5% BSA in PBS) and were stained with the anti-Claudin 5 
primary antibody for 1h at RT. Then, the Alexa-488 anti-Mouse secondary antibody diluted 
in BB was incubated 1h at RT. In order to detect actin filaments, TRITC-Phalloidin 
(Sigma) was used. After fixation and permeabilization, bEnd.3 cells were incubated for 30 
minutes at RT. For nuclei staining DAPI was used. All samples were then observed at 
confocal microscope (Leica TCS SP5 MP ) with a 25 × water-immersion objective. 
5.4.7 TEER measurements 
 
TEER measurements were carried out by connecting the BBB chip to an AUTOLAB 
PGSTAT302N (potentiostat/galvanostat) equipped with a FRA32M module (frequency 
response analysis module). Impedance spectra were recorded in potentiostatic mode with an 
amplitude of 0.01V and frequencies ranging from 100kHz to 0.1Hz between two Pt 
electrodes. Pt electrodes were realized by sputtering deposition of 20 nm of platinum on the 
surface of metallic microfluidic tips with a final diameter of 1.3 mm.  For each 
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measurement 3 readings and 50 data points (logarithmic frequency step) per reading were 
collected. The least-square optimization method was used to fit the measured impedance 
data to an electrical equivalent circuit model, reported in Fig. 9. 
  
 
 
In the adopted model the constant phase element represents the dual layer capacitance of Pt 
electrodes (CPEdl), which is in series with the resistance of the medium (Rmedium) and the 
cell monolayer, which is denoted as the resistance of cell (Rteer) and the capacitance of the 
cell membrane (Ccl) in parallel. Porous polymeric membrane was used as supporting 
material for cells adhesion and growing. This membrane represents an additional resistive 
term (Rmem) which is in parallel with Rteer. Thus, for each impedance spectra an apparent 
Rteer (Req) was collected and then corrected (eq. 1) for the membrane resistance to obtain 
the effective Rteer.   
Rteer=(Req*Rmem)/(Req+Rmem) 
Rteer was normalized for the cross sectional surface area of the chip (0.054 cm2) to 
calculate TEER value in Ohm*cm2. 
 
 
5.4.8 Transport assay 
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Transport experiments across the BBB microfluidic system were performed at the 7
th
 day 
after seeding. Briefly, a 5 ml syringe was loaded with a FITC-BSA solution at the final 
concentration of 0.1 mg/ml in cell culture medium supplemented with 40 mM HEPES 
buffer. For nanoparticle transport experiments, the syringe was loaded with blank and 
gH625-NP suspensions in buffered cell culture medium at the final concentration of 9.20 × 
10
10
 and 1.84 × 10
10
 NP/ml. The syringe was then allocated on a syringe pump (Harvard 
Apparatus Pump 11 Elite) connected to the inlet of the microfluidic system by a tube 
(Radel Tubing 1/16x020xsoft). The outlet of the system was connected to an Eppendorf 
tube through the same kind of tube in order to collect the output flow media. The collection 
chamber was filled with 90 µl of cell culture medium. The experiments were carried out in 
a plexiglass incubator at 37 °C and solutions are flowed at 5 or 25 µl/min flow rates. 
Compounds and NPs that cross the endothelial monolayer are collected in the apical 
chamber. Experiments were carried out for 3 h, drawing the medium in the collection 
chamber every 30 minutes and replacing it with fresh medium. The transport of BSA and 
nanoparticles across the BBB layer was estimated by fluorescence measurements through a 
spectrofluorometer (Perkin-Elmer, USA). Data were reported as the percentage of 
transported BSA and NPs compared to the initial concentrations of the fluorescent 
compounds. 
5.4.9 Image analysis 
 
In order to quantify the amount of NPs in the cells, after NP transport experiment under 
flow conditions, bEnd.3 cells were fixed in the microfluidic system and stained with DAPI. 
Five images for each sample were acquired by confocal microscope and analyzed. The 
quantification of fluorescent NPs was performed by using area calculator plugins of ImageJ 
software. Data were reported as fluorescent areas normalized to the number of the cell 
nuclei.  
5.4.10 Statistical analysis 
 
Results were expressed as mean ± standard deviation (SD). Results repeats were compared 
by a one-way analysis of variance (ANOVA), and a p value < 0.05 was considered 
statistically significant. 
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5.5 CONCLUSIONS 
 
The goal of this work has been to set up a BBB microfluidic system which is able to 
investigate the effects of the flow on bioconjugated nanoparticles surface. The microfluidic 
system made of PMMA, has an high degree of biocompatibility with biological tissue. 
Furthermore, transparency of the PMMA allows to monitor the growth of cerebral 
endothelial layer. A protocol of cell seeding and culture in the system has been developed 
and cells are able to grow, reach the confluency and express the tight junctions up to 7 days 
from the seeding. These data were confirmed by phase contrast and confocal images of 
endothelial cell layer in the system channel and TEER results suggest that the in vitro BBB 
reproduces the key physiological and biological characteristics of a BBB model. 
Nanoparticles are able to cross the porous filter in the microfluidic system and the presence 
of cell monolayer reduce NP transport which depends on flow rate and NP concentration. In 
order to evaluate the effects of flow conditions on crossing of the CPP gH625 in 
transporting NP across the BBB, firstly, 5 µl/min has been selected as working flow rate 
because it does not affect the cell monolayer integrity. The interactions between gH-NPs 
and in vitro brain endothelium, to predict the rate of NP delivery across the BBB, has been 
evaluated to understand mechanisms of barrier transport, under dynamic condition. 
Reported here is that the conjugation of gH625 on the surface of polystyrene NPs facilitated 
the delivery of nanoparticles across the BBB, leading to signiﬁcant higher cell uptake and 
crossing under flow condition, by using a microfluidic system. Taken all together these data 
suggest that in vitro BBB microfluidic system could represent a promising platform for NP 
transport assays. The home-made device is able to investigate the effects of dynamic 
conditions on specific targeting and transport across the brain endothelium of active 
peptides conjugated to nanocarriers. The system allows reproducibility of experiments and 
allows the quantification of transport of molecules and nanoparticles across the BBB in 
vitro. More interestingly, gH-NPs could be regarded as a promising strategy to design 
delivery systems for administration of therapeutical compounds to the brain, deserving 
further investigations to more precisely characterize the mechanism by which gH625 
crosses the BBB and to address the cell speciﬁcity issue by linking to the nanosystem also 
molecules speciﬁcally recognized by the brain endothelium. 
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6 CONCLUSIONS 
 
The applications of nanoparticles for drug delivery demonstrated to have a significant 
impact in particular on area of medicine for brain treatments. Nevertheless, drugs delivered 
inappropriately can produce side effects to healthy tissues and can hamper reaching the 
threshold dose to be effective in the target sites. In order to overcome these limits, a precise 
control of nanoparticles on BBB targeting and crossing is needful. In this context, this 
thesis deals with the importance of defining the optimal physico-chemical properties for a 
rational design in order to obtain a more specific BBB targeting and transport of 
nanoparticles. Biodegradable nanoparticles made up of PELGA polymers functionalized 
with CRT and gH625 peptides able to recognize the TfRs over-expressed on cerebral 
endothelium and to transport nanoparticles across the BBB have been developed and 
characterized. Results confirmed the effectiveness of both CRT and gH625 peptides in 
transporting nanoparticle across the BBB, specifically, in a synergistic manner. For a better 
understanding of NP behavior, a microfluidic BBB model system that mimics blood flow 
has been developed. Through permeability assays the system can be used to predict the rate 
of delivery of new NPs across the BBB. Experiments demonstrated the versatile potential 
of this microfluidic platform. Thus, the use of the fabricated microfluidic BBB model could 
be a valid option for pre-clinical studies. 
Collectively, the data obtained also indicate that further investigation of the dual-
functionalized NP permeability across the microfluidic BBB model is necessary in order to 
predict the rate of NP delivery through the cerebral endothelium under dynamic conditions. 
The produced NPs hold promise as a useful tool to improve therapeutic efficacy for 
treatment of brain diseases. 
 
